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ABSTRACT 
This dissertation presents methods for the evaluation of ocular surface protection 
during natural blink function. The evaluation of ocular surface protection is 
especially important in the diagnosis of dry eye and the evaluation of dry eye 
severity in clinical trials. Dry eye is a highly prevalent disease affecting vast 
numbers (between 11% and 22%) of an aging population. There is only one 
approved therapy with limited efficacy, which results in a huge unmet need. The 
reason so few drugs have reached approval is a lack of a recognized therapeutic 
pathway with reproducible endpoints. While the interplay between blink function 
and ocular surface protection has long been recognized, all currently used 
evaluation techniques have addressed blink function in isolation from tear film 
stability, the gold standard of which is Tear Film Break-Up Time (TFBUT).  
In the first part of this research a manual technique of calculating ocular 
surface protection during natural blink function through the use of video analysis 
is developed and evaluated for it’s ability to differentiate between dry eye and 
normal subjects, the results are compared with that of TFBUT. In the second part 
of this research the technique is improved in precision and automated through the 
use of video analysis algorithms. This software, called the OPI 2.0 System, is 
evaluated for accuracy and precision, and comparisons are made between the OPI 
2.0 System and other currently recognized dry eye diagnostic techniques (e.g. 
TFBUT). In the third part of this research the OPI 2.0 System is deployed for use 
in the evaluation of subjects before, immediately after and 30 minutes after 
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exposure to a controlled adverse environment (CAE), once again the results are 
compared and contrasted against commonly used dry eye endpoints.  
The results demonstrate that the evaluation of ocular surface protection 
using the OPI 2.0 System offers superior accuracy to the current standard, 
TFBUT. 
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CHAPTER 1 
INTRODUCTION 
 
The focus of this research is in the development of an accurate and precise 
endpoint for the evaluation of ocular surface protection for use in the diagnosis 
and evaluation of dry eye.  Dry eye is a highly prevalent disease affecting vast 
numbers (between 11% and 22%) (Brewitt & Sistani, 2001) of an aging 
population. There is only one approved therapy with limited efficacy resulting in 
a huge unmet need. The reason so few drugs have reached approval is a lack of a 
recognized therapeutic pathway with accurate, reproducible endpoints. Compiling 
the complexities in this area of development is a large array of trial designs as 
well as constantly changing environmental factors. The value of a reliable 
clinically meaningful endpoint can only be recognized in the context of a 
therapeutic pathway in the approval process. A therapeutic pathway pertains 
specifically to the efficacy of a drug and the way in which that drug acts on the 
disease it is predicted to improve. It is this pathway that links how a disease is 
diagnosed to the most efficacious treatment. Drugs are approved based upon two 
main criteria, Safety and Efficacy.  
As the audience of the papers contained in this dissertation are in the 
medical field and therefore the clinical relevance of the methods developed herein 
were of most interest rather than the engineering tools deployed to accomplish 
this work, the style in which this dissertation reads is a bit different than that of 
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most engineering Dissertations; that being said the tool used to complete this 
work include Human factors engineering, DOE (Design of Experiments), 
computer science engineering, image analysis, Verification and Validation of 
systems, non-parametric modeling, generalized Linear models and six sigma 
methodologies. 
This research was spawned out of identification Tear film Breakup Time 
(TFBUT), the gold standard measurement of tear film stability developed in 1973 
and used worldwide by ophthalmologists and clinicians to evaluate dry eye 
severity, had unreasonably high variability. In analyzing the process it was 
determined that a full redesign of the process was necessary and that a higher 
degree of reliability and reproducibility could be achieved. Through the use of 
FMEA and the DMAIC process we redesigned, improved, optimized and 
stabilized the process. It was this engineering approach that made this research 
possible and through the deployment of the tools mentioned above successful.  
Clinical development of an ophthalmic drug begins with submission of an 
Investigational New Drug (IND) application to the United States Food and Drug 
Administration (FDA).1 This submission occurs after sufficient preclinical data 
determining the compound’s reasonable safety and pharmacological activity is 
gathered, and marks the beginning of the FDA’s involvement in the drug 
development process. The IND is required to include summaries of results of 
animal pharmacology and toxicology as well as any prior use in humans (typically 
                                               
1
 With the exception of ophthalmic formulations meeting the requirements of 21 CFR part 349 
(“Ophthalmic Drug Products for Over-the-Counter Human Use”). 
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pertains to foreign use); manufacturing information to ensure adequate production 
and batch consistency capabilities; and detailed protocols and investigator 
information for proposed clinical research. Following IND submission, the 
sponsor is required to wait 30 days prior to initiating clinical trials, during which 
time the FDA has the opportunity to review the IND for subject safety concerns.  
The International Conference on Harmonisation (ICH) Guidance on 
General Considerations for Clinical Trials “discusses the recognized principles 
and practices in the conduct of clinical trials and the development strategy for 
new drug products”(1997) The clinical development pathway of a drug typically 
consists of three general phases, described as the following: Phase I as the initial 
administration of an investigational new drug in humans, Phase II being the 
exploration of therapeutic efficacy in patients, and Phase III as the demonstration 
or confirmation of the drug’s therapeutic benefit.  Phase IV studies are those 
performed subsequent to drug approval. In the design of clinical trials, the 
guidelines state that primary endpoints should be selected clinically relevant 
measurements. Secondary endpoints may or may not be related to the primary 
endpoint. Furthermore, the methodology involved in measuring these endpoints 
“should be validated and meet appropriate standards for accuracy, precision, 
reproducibility, reliability, and responsiveness (sensitivity to change over 
time)(FDA, 1997) ”.  
When the sponsor (i.e. pharmaceutical company, academic institution, 
etc.) believes that the results of these studies adequately demonstrate the drug’s 
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safety and effectiveness, the next step is to submit a New Drug Application 
(NDA)(FDA, 2009). The NDA serves as an application to market the drug and 
includes all information available on the drug to-date as well as proposed labeling 
information in the form of a proposed package insert. The application must 
provide adequate information and analyses for FDA reviewers to review to 
determine: (1) whether the drug can be deemed safe and effective in its proposed 
uses, and whether the benefits outweigh any risks incurred by the drug; (2) 
whether the drug’s proposed package insert is appropriate and what it should 
contain; and (3) whether the manufacturing methods and controls supply 
sufficiently preserve the drug’s identity, strength, quality, and purity (FDA, 
2009). No new drug can be legally marketed in the United States without FDA 
approval of an NDA, unless recognized as safe and effective for its intended use, 
as in the case of over-the-counter products described in a drug monograph(Lloyd, 
Harris, Wadhwa, & Chambers, 2008). 
Within 60 days of the FDA receiving an NDA, the agency must determine 
filability of the application. In the case of incomplete or deficient applications, the 
FDA may take a refuse to file action. If the FDA determines that the package is 
contents are adequate for review, a filable action is taken. Once deemed filable, 
the agency has either 6 (priority review for therapies representing a significant 
therapeutic advance) or 10 (standard review) months to complete the regulatory 
decision (Lloyd, et al., 2008). The decision is based on the goal of establishing the 
safety and efficacy of the drug product for the indicated use. Although the 
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meaning of the phrase “safe and effective” can be subjective, the FDA language is 
based on the Federal Food Drug and Cosmetic Act and explains that the 
application must include “full reports of investigations which have been made to 
show whether or not such drug is safe for use and whether such drug is effective 
in use” (ICH, 2009; Schachat, Chambers, Liesegang, & Albert, 2003) . Advisory 
committees (composed of FDA-appointed doctors, scientists, industry 
representatives, etc) may be convened in order to provide public input on the drug 
product, and provide nonbinding advice to the FDA regarding approval. At the 
completion of NDA review, the FDA issues one of three regulatory actions: 
approval, approvable, or not approvable; which denote marketability, requirement 
of further information and potential additional clinical trial completion, and no 
approval at this time (for any of a variety of reasons), respectively (Lloyd, et al., 
2008).  
 
Efficacy Endpoints 
 The role of endpoints outlined in clinical trial protocols is to assess drug 
effects (i.e. related to pharmacokinetics, pharmacodynamics, efficacy, and/or 
safety) (FDA, 1997). There should be adequate evidence of the reliability and 
validation of primary variables in regards to clinical relevance and treatment 
benefit in the population studied (ICH, 2009). The methods used to measure both 
subjective and objective endpoints, “should be validated and meet appropriate 
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standards for accuracy, precision, reproducibility, reliability, and responsiveness 
(sensitivity to change over time)”(FDA, 1997).  
  
Dry Eye: The unmet need for treatment 
 Estimates of dry eye prevalence vary with the populations studied and 
parameters defining diagnosis, and reports range from roughly 11% to 22% 
(Brewitt & Sistani, 2001) Normally, the human tear film is a complex solution of 
various aqueous, lipid, and mucin components in a fragile balance, and protects 
and nourishes the ocular surface. When the homeostasis is interrupted by any of a 
multitude of factors, the tear film can become unstable and dry eye results. 
Research over the years has unveiled risk factors that include use of systemic 
medications with ocular drying effects (e.g. antihistamines, tricyclic 
antidepressants, diuretics), systemic disease (e.g. autoimmune, rheumatic), and 
altered innervation (e.g. damage to the fifth cranial nerve, metabolic deficiencies, 
modified blinking patterns), but other risk factors such as cigarette smoking, acne, 
and alcohol use are still under debate.(M. B. Abelson, Ousler, & Maffei, 2009) 
("The epidemiology of dry eye disease: report of the Epidemiology Subcommittee 
of the International Dry Eye WorkShop (2007)," 2007) Real-world challenges 
such as prolonged visual tasking, contact lens wear, and exposure to windy, hot, 
arid environments can destabilize the tear film or further endanger an already 
compromised tear film as well. 
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 The pathophysiologies encompassed under the blanket term of “dry eye” 
run the gamut of highly symptomatic patients who display no clinical signs 
associated with dry eye to patients demonstrating severe signs of dry eye, but who 
elicit minimal to no symptomatic complaints (G. W. Ousler, 3rd, Hagberg, 
Schindelar, Welch, & Abelson, 2008). Symptoms associated with dry eye include 
complaints of: burning, stinging, grittiness, discomfort, photophobia, blurred 
vision, etc. One dry eye patient may experience excessive tearing as a result of 
physiological compensatory attempts in response to insufficient lubrication, while 
another experiences constant symptoms of dryness and grittiness. Clinical signs 
include: conjunctival hyperemia (redness), ocular surface staining (cell damage), 
shortened tear film break-up time (TFBUT) (unstable tear film), decreased tear 
production, etc.  
Once diagnosed, treatment is the next challenge. Over-the-counter (OTC) 
ocular lubricants (also known as “artificial tears” or “tear substitutes”) are the 
mainstay in dry eye treatment today. The assorted formulations available include: 
single- or multi-dose packaging, preserved or unpreserved solutions, varied active 
and inactive ingredients, etc, and these formulations are marketed in accordance 
with the FDA monograph entitled, “Ophthalmic Drug Products for Over-the-
Counter Human Use”(FDA, 1988). Studies have demonstrated prolonged 
TFBUT, enhanced ocular surface protection between blinks, and improved 
symptomatic conditions through the use of these drops, but the formulations 
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typically provide only transient relief and apply mostly to mild-to-moderate cases 
of dry eye or as adjuvant to therapy in more severe cases. 
A biodegradable polymeric ophthalmic insert designed for prolonged 
lubrication via insertion into the subconjunctival sac and subsequent dissolution 
by natural tears is also available by prescription, but can cause visual blurring and 
may present problems in patients with substantially decreased tear production 
(Lacrisert [prescribing information], 2007). Only one eye drop, cyclosporine 
0.05% (Restasis, Allergan) has been approved by the FDA for the treatment of 
dry eye, and even this therapy has a limited indication to, “increase tear 
production in patients whose tear production is presumed to be suppressed due to 
ocular inflammation associated with keratoconjunctivitis sicca”. The labeling also 
states that, “increased tear production was not seen in patients currently taking 
topical anti-inflammatory drugs or using punctal plugs” and that statistically 
significant increases in tear production was only observed in 15% of treated 
patients (Restasis [prescribing information], 2009) Other modes of dry eye 
treatment include implantable punctal plugs (tears exit the eye through the 
punctum) for tear retention and corticosteroids and systemic tetracycline are used 
(for more severe cases), but the efficacy of the former is controversial and the 
latter two are off-label uses which introduce the risk of side effects (Pflugfelder, 
2004). 
Agents currently in development for the disease include those targeting the 
mucin components of the tear film (mucin secretagogues—agents that stimulate 
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mucin secretion and mucogenics—agents that synthesize mucin), anti-
inflammatory agents of varying mechanisms of action, and a combination 
corticosteroid/iontophoretic device (see Table 1.1). Ideally, treatments will 
eventually be tailored toward different pathophysiologies of dry eye. While FDA 
approval presents a substantial challenge, the market situation illustrates a 
considerable population of dry eye patients left underserved by available 
treatments, and represents tremendous opportunity for clinical development 
improvement and therapeutic advancement. 
 
Table 1.1. Agents in development for dry eye treatment 
Agent Company Class 
Cyclosporine A Novagali Pharma 
www.novagali.com Anti-inflammatory 
Dexamethasone phosphate  
via ocular iontophoresis 
EyeGate Pharma 
www.eyegatepharma.com Anti-inflammatory 
Diquafosol tetrasodium Inspire Pharmaceuticals 
www.inspirepharm.com Mucin secretagogue 
Doxycycline  
(nonantimicrobial) 
Alacrity Biosciences 
www.alacritybio.com Anti-inflammatory 
Ecabet sodium ISTA Pharmaceuticals 
www.istavision.com Mucin secretagogue 
MIM-D3 Mimetogen Pharmaceuticals 
www.mimetogen.com Mucin secretagogue 
Rebamipide Otsuka Pharmaceuticals 
www.otsuka-global.com 
Mucogenic/ 
Mucin secretagogue 
RX-10045  
(resolvin therapy) 
Resolvyx Pharmaceuticals 
www.resolvyx.com Anti-inflammatory 
SAR 1118  
(LFA-1 antagonist) 
SARcode 
www.sarcode.com Anti-inflammatory 
Voclosporin Lux Biosciences 
www.luxbio.com Anti-inflammatory 
 
Diagnostics and Clinical Models 
 Precise clinical models are integral to successful evaluation in drug 
development; Still, many clinical trials consist purely of environmental exposure 
components, which introduce variability between subjects (e.g. time spent at work 
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using a computer, time spent outdoors, relative humidity flux, etc). To control this 
variability, the Controlled Adverse Environment (CAE) model (Developed by Ora 
Inc.) was designed to exacerbate ocular signs and symptoms in a reproducible 
manner, but pertains to particular factors known to aggravate dry eye conditions 
rather than the allergic response. Lighting, airflow, temperature, humidity, and 
visual tasking parameters are precisely controlled in a chamber in order to provide 
a consistent challenge to the tear film and ocular surface that emulates real-world 
drying situations. The major advantage of the CAE model is that the 
environmental parameters are maintained in precise ranges, minimizing 
fluctuation (G. W. Ousler, Gomes, Welch, & Abelson, 2005). Typical CAE study 
designs include a screening visit to establish each individual’s baseline response 
and ensure that this response is representative of the target treatment group, a 
confirmatory visit to ensure that the signs and symptoms observed at baseline are 
reproduced at a later time point, and various CAE re-challenges to treated eyes. 
The successful completion of numerous clinical studies utilizing the CAE model 
illustrates its applicability to the research and development in dry eye. (Crampton, 
et al., 2007b; Emory, Ousler III, & Abelson, 2003; Kellerman, et al., 2004; G. W. 
Ousler, 3rd, Abelson, Nally, Welch, & Casavant, 2002; G. W. Ousler, 3rd, 
Anderson, & Osborn, 2008; Ousler GW, Gomes PJ, Crampton HJ, & MB., 1999; 
G. W. I. I. I. Ousler, Canova, Nentwig, Welch, & Abelson, 2009; Ousler III, 
Haque, Weichselberger, Yannoulis, & Abelson, 2005; Ousler III, Welch, & 
Abelson, 2004; Pratt, Ousler III, Schindelar, Chapin, & Abelson, 2005) 
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 Another clinical tool designed for dry eye research is the Ocular 
Protection Index (OPI) (G. W. Ousler, 3rd, Hagberg, et al., 2008). The original 
OPI is calculated as the quotient of TFBUT divided by inter-blink interval (IBI, 
the average number of seconds between blinks). The TFBUT variable is assessed 
by the clinician asking the patient to blink twice and then stare, and represents the 
number of seconds between eye opening after the second blink (beginning of the 
stare) and the appearance of the first expanding break in the tear film. The IBI 
variable is typically calculated by capturing a fixed gaze blink rate (video-
recorded using a headset microcamera during completion of a standardized visual 
task) and computing the average number of blinks per minute and subsequently 
the average number of seconds between blinks. The OPI represents a binary 
variable of average ocular surface protection: an OPI ≥ 1.0 denotes sufficient 
ocular surface protection, while an OPI < 1.0 denotes insufficient ocular surface 
protection. The latter situation may indicate a compromised ocular surface and the 
need for tear film stabilization. The allure of this metric is two-fold: its simplicity 
and, more importantly, its applicability across disease subpopulations. In essence, 
because all manifestations of dry eye are characterized by tear film instability, the 
OPI is a common denominator of all etiologies and pathophysiologies. 
Technological advances have since been developed to more accurately 
measure and represent the state of ocular surface protection and exposure supplied 
by the tear film. (R. Abelson, et al., 2011) But unlike these other techniques the 
methods developed in this research take advantage of real-time video capture and 
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subsequent analysis of blink rate and TFBUT simultaneously, thereby eliminating 
the questions instilled by the separate capture of IBI and TFBUT in the original 
metric. The analysis is performed using a computer program consisting of a 
template matching algorithm and a specific threshold for indication of a blink in 
the series of video frames (R. Abelson, et al., 2012). The enhanced metric also 
allows for interpretation of partial blinks in addition to complete, and incorporates 
real exposure calculation capabilities. 
 
Meeting regulatory requirements 
 The technological advances made require compliance with several 
regulatory guidelines. Because the OPI 2.0 system utilizes electronic capture and 
analysis of data, it must meet the requirements of the Code of Federal 
Regulation’s “Electronic Records; Electronic Signatures”. Key requirements 
include system validation, ability to generate duplicate records for FDA 
inspection, adequate protection of the records, use of secure and accurate audit 
trails (via computer-generated time stamps when user creates, modifies, or deletes 
records), electronic signatures, use of a series of checks (operational, authority, 
device), and adequate training of system users (FDA).The document clearly states 
that the procedures used in electronic records include system validation, “to 
ensure accuracy, reliability, consistent intended performance, and the ability to 
discern invalid or altered records”. The revised OPI metric involves video capture 
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of patient data subsequent analyses, technician and doctor review, and storage of 
these data, all of which apply to the regulations for electronic records. 
 Revisiting the OPI metric, research identified shortcomings in the real-
world applicability of the original OPI as well as potential opportunities for 
improved accuracy. In two identical clinical studies, results were found to be 
inconsistent for OPI while the results for other endpoints evaluated remained 
much more consistent. A review of the process through which Blink Rate and 
Tear Film Break Up Time were evaluated. Blink Rate was evaluated using a 
ISCANtm (Burlington, MA) blink counter. The blink counter consists of a headset 
that fits over the head of the patient and a camera points at the eye under 
evaluation. As the blinks are recorded with the video camera a program in the 
background counts the blinks. If the camera is set up incorrectly or the patient is 
wearing eyeliner, the counter could have a difficult time accurately counting the 
blinks. As the program runs simultaneously to the evaluation and the videos are 
not saved, there is no method for any type of post-hoc evaluation of the accuracy 
of the video. Through manipulation of the system dump files with patient’s blink 
data was created, and simultaneously another video camera was used to capture 
the actual blink. After gathering a few patients’ data the blink rate was manually 
assessed from the recorded video and compared to the output from the blink 
counter.   Minimal analysis revealed that there was a substantial amount of error 
generated by the blink counter. Secondly, a review of the method for measuring 
Tear film Break Up Time was completed, which consists of an Ophthalmologist 
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watching the patient’s eye through a slit lamp and assessing the time of break up 
using a stop watch. This is done once on each eye and a single sample is taken for 
each. Thereby, a patient could have two different measures of TFBUT with a 
single measure of blink rate. The Blink rate and TFBUT assessments are done at 
different time points and the OPI measurement calculated later. It was very 
apparent that this method for estimating if a patient’s eye was protected was 
fraught with issues (shortcomings). In the list below find some of the major ones: 
 
• Operator error 
• Blink Rate Counter Machine error 
• Sample size of TFBUT 
• TFBUT evaluated at a different time than blink rate. 
• Measurement error in both Blink Rate and TFBUT 
There were two main opportunities identified. The first was that it would be of 
interest not only to evaluate the time of the cornea exposure (Calonge, 2001), but 
the actual area of exposure over time. The second opportunity was to evaluate 
Blink and Tear Film Break Up Time within a patient’s normal blink pattern rather 
than Blink at one time point and TFBUT at another.  
In the first paper, a manual technique to accurately measure the area of 
ocular protection during a normal blink pattern is presented. This technique while 
proven to be reasonably accurate and sufficient to meet the goal of differentiating 
between dry eye patients and normal patients, is very manually intensive and uses 
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estimation to calculate the area of corneal exposure over time. To make this a 
scalable technique that could be used as a viable endpoint on larger trials, the 
technique needed to become more efficient, less manual and less computationally 
intensive.  
Therefore, in the second paper, an almost fully automated technique is 
presented using a video analysis program. This new methodology, outlined in the 
flow chart below (Figure 1.1), employs commonly used video analysis methods 
to detect pixel density differences between a baseline image of a fully protected 
tear film and subsequent images.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.1. Flow Chart of Video analysis method.
 
 
 
Through the use of these video analysis techniques, the percent of corneal 
exposure in any given image can be estimated. As the video camera takes 15 
16
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frames per second and videos last approximately one minute, 900 data points are 
captured to reveal the performance of a given patient. This data, displayed 
graphically in Figure 1.2 with Time on the x-axis and Percent of Corneal 
Exposure on the Y-axis, results in a very intuitive representation of the underlying 
pathophysiology of the eye at any point in time. 
 
Figure 1.2. Graph of Percent Exposed Cornea vs. Time.  
 
 
 
In the above graph the vertical lines represent blinks and the sloped lines in 
between the blinks demonstrate the percent of corneal exposure at that given time 
point. The increasing exposure over time until the patient blinks again is apparent. 
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At around 700 frames this particular patient has a partial blink that doesn’t fully 
refresh the tear film.   
After outlining and discussing the new analysis methodology of the video 
technique the second paper presents results showing the use of this tool in 
differentiating between dry eye and normal subjects. A detailed discussion of 
verification and validation techniques employed are also presented.  
In the third paper the OPI 2.0 System is used to evaluate patients before, 
immediately after and 30 minutes after exposure in the CAE. The results 
demonstrate the additional information the MBA variable provides in 
understanding subject response. TFBUT is also evaluated at the same time points 
and demonstrates poor correlation to MBA, discomfort, staining and changes in 
fissure width. The data provided suggests that TFBUT lacks the precision to be a 
useful parameter in evaluating the signs of Dry Eye.  
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CHAPTER 2 
MEASUREMENT OF OCULAR SURFACE PROTECTION UNDER 
NATURAL BLINK CONDITIONS 
 
 
Background 
 
The ocular surface and its individual components make up the protective barrier 
between the eye and the outside world.  It is regularly challenged by the 
environment (eg, low humidity, wind exposure, pollutants) as well as disease (eg, 
autoimmune disease, neurologic disease).(G. W. Ousler, et al., 2005)  In response 
to these challenges, the ocular surface and its components are in a highly dynamic 
state constantly adjusting to different environmental and biologic 
conditions.(Rolando & Zierhut, 2001)  Secretions from the main and accessory 
lacrimal glands, meibomian glands, and conjunctival goblet cells provide the 
aqueous, lipid, and mucin components, respectively, of the human tear 
film.(Chao, Vergnes, Freeman, & Brown, 1980; Mishima & Maurice, 1961; 
Nagyova & Tiffany, 1999; Nguyen, Beuerman, Meneray, & Maitchouk, 1998; 
Rolando, Refojo, & Kenyon, 1985; Rolando & Zierhut, 2001)  The tear film 
serves three main functions: protection of ocular surface epithelial cells from 
desiccation, nourishment of the epithelium, and optical refraction.  Interruption of 
the fragile homeostasis of the tear film via insufficiencies in either the quality or 
quantity of its constituents can result in tear film instability and may lead to 
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surface damage.  Such surface damage is often characteristic of the many 
pathophysiologies of dry eye disease.   
The relationships between the time between successive blinks, or the 
interblink interval (IBI), and tear film breakup time (TFBUT), the time from the 
completion of a blink to the appearance of the first dry spot, or micelle on the 
cornea, define the integrity of the ocular surface.(M. B. Abelson, Ousler, Nally, 
Welch, & Krenzer, 2002; Holly, 1973; Lemp, 1973; Lemp, Goldberg, & Roddy, 
1975; Smith, Nichols, & Baldwin, 2008)  Accordingly, both IBI and TFBUT are 
meaningful variables to characterize in efforts to better understand dry eye.  As a 
standard diagnostic test for over 40 years, TFBUT has been traditionally 
measured during a forced-stare following 2 forced, complete blinks by an 
observer with a stopwatch observing the fluorescein-stained ocular surface 
through a slit lamp.(M. B. Abelson, et al., 2002; G. W. Ousler, 3rd, Hagberg, et 
al., 2008)  
The Ocular Protection Index (OPI) was developed to capture the nature of 
the interaction between blinking and TFBUT, and the OPI methodology has been 
used in numerous observational studies and clinical trials.(Crampton, et al., 
2007a; D'Arienzo, Ousler III, & Schindelar, 2007; G. W. Ousler, Emory, Welch, 
& Abelson, 2002b; G. W. Ousler, Michaelson, & Christensen, 2007; Wilcox 
Hagberg, Ousler III, Casavant, Welch, & Abelson, 2005b)  The OPI is calculated 
by dividing the TFBUT by the inter-blink interval (IBI).(G. W. Ousler, 3rd, 
Hagberg, et al., 2008)  In an ideal state, tear film break up does not occur prior to 
  
21
the next blink (i.e. TFBUT > IBI).  Based on this assumption, if the OPI is < 1, a 
patient’s cornea is considered at risk for exposure, resulting in the development or 
exacerbation of dry eye signs and symptoms, and if the OPI is ≥ 1, a patient’s 
cornea is considered to be protected, presumably resulting in fewer dry eye signs 
and symptoms.(G. W. Ousler, 3rd, Hagberg, et al., 2008)      
While the use of OPI provides context for determining the clinical 
relevance of TFBUT, our increased understanding of the complexities of blink 
physiology and tear film breakup suggests that the traditional methodology has a 
number of shortcomings:  
(1) Data collected at different times:  The TFBUT measurement and the IBI 
measurement are performed at different times.  Blink rate is captured under 
normal blink conditions while the subject watches video, while TFBUT is 
measured separately.  
(2) Data collected under unnatural physiological conditions:  TFBUT is 
evaluated using the forced-stare technique, which is an unnatural physiological 
condition.    
(3) Potential confounding factors:  The forced stare may introduce complications 
such as reflex tearing and increased ocular discomfort.  The manual measurement 
of TFBUT with a stopwatch introduces imprecision and variability.  The use of a 
stopwatch innately introduces human error into the manual measurement of 
TFBUT as there is an inherent delay between the time the doctor can detect a 
break and the time the stopwatch is stopped.   The blink rate method used (video 
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capture headset and associated software) counts only complete blinks.  The 
inclusion of other types of blinks in the evaluation should yield a more accurate 
depiction of the degree of protection at the corneal surface.  In addition, the use of 
a single time provides no information on the area of corneal surface exposed, or 
rate of the change in the exposed area as a function of time during the IBI. 
To address the shortcomings of the traditional (Forced-Stare, FS) 
methodology, this paper evaluates an alternative method for the evaluation of 
ocular surface protection under normal visual conditions.  Briefly, the method 
involves retrospective analysis of video data of fluorescein-stained eyes taken 
through a slit lamp while the subject watches television.  The retrospective 
analysis provides the area of tear film breakup for each IBI during the one-minute 
video.  This technique is called Video Capture Manual Analysis (VCMA) and is 
described in more detail below.  A study was performed and data are presented 
that compare the traditional (FS) and new (VCMA) methodologies.  We 
demonstrate the ability of the new (VCMA) method to distinguish between 
normal and dry eye subjects and to identify post-treatment changes in dry eye 
subjects following the instillation of an artificial tear solution.     
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Methods 
Measurement Techniques 
Table 2.1 provides a list of definitions of variables analyzed. 
 
Table 2.1. Definitions of variables analyzed 
Measured Variables Definition 
TFBUT (breakup time) Time in seconds from a blink until the first 
appearance of tear film break up 
IBI (inter-blink interval) traditional Time in seconds between complete blinks  
(>95% of the pupil covered) 
IBI (inter-blink interval) new Time in seconds between any blinks 
BUA (breakup area) 
Fraction of the cornea surface showing 
evidence of tear film breakup, as measured 
with the 17-zone corneal transect, at the end 
of the IBI.   Units are % (percent of the 
corneal surface showing breakup)   
Rate 
Rate of increase in breakup area as a 
function of time during the time-exposed 
interval (see Figure 2).  Units are % per 
second 
Derived Variables Definition 
BUA/IBI Breakup area divided by the inter-blink 
interval.  Units are % per second 
 
 
Traditional (FS) Method: 
Primary-Gaze Blink Rate:  Blink rate was measured using the IScan™ system 
(Burlington, MA) which consists of a headset (including a digital micro-camera 
and an infrared illuminator to track the diameter of the pupil) worn by the patient 
to non-invasively record blinks.  Only complete blinks were counted, defined as > 
95% of pupil coverage.  During the blink rate evaluation, subjects were isolated 
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and were asked to watch a video image.  The IBI was calculated by dividing the 
total number of complete blinks by the total time. 
 
Forced-Stare TFBUT:  Sodium fluorescein solution (5µl, 2% preservative-free) 
was instilled into the inferior conjunctival cul-de-sac of each eye and the subject 
was asked to blink several times to mix the fluorescein with their tear film.  The 
subject was then asked to blink twice (squeeze-blinks) and then stare without 
blinking for as long as possible.  The examiner monitored the integrity of the tear 
film through a slit-lamp biomicroscope with an 8 mm scanning beam (using an 
excitation blue filter and a barrier Wratten #12 yellow filter), and measured the 
time from eye opening to the first appearance of micelles with a stopwatch.  The 
eyes were evaluated sequentially (OD, OS).  Two measurements were taken and 
averaged unless the two measurements were both less than  10 seconds and 
differed by more than 2 seconds, in which case a third measurement was taken 
and the two closest of the three were averaged.   
 
New (VCMA) Method: 
Video of Fluorescein-Stained Eyes: Sodium fluorescein was instilled as described 
above.  While the subject performed a standard visual task (watching a 
documentary on television from a five foot viewing distance), the eye was 
recorded using a digital video camera (EYECAP IM 900 camera system) at 8x 
magnification through a slit-lamp biomicroscope using an excitation blue filter 
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and a barrier Wratten #12 yellow filter.  A minimum of one minute of continuous 
data was recorded for each eye with roughly a thirty second pause between 
recordings of the two eyes.  The eyes were recorded from right (OD) to left (OS).   
 
Retrospective Manual Analysis: A retrospective analysis of the data from each 
eye was performed to generate TFBUT, IBI, and BUA over the 1 minute period.  
A panel of examiners evaluated the integrity of the tear film and determined IBI 
and TFBUT by manually stopping the video to note and confirm the time stamp, 
and record the time of each blink and the first appearance of a micelle within each 
IBI.   
Videos were analyzed for BUA using a corneal transect comprising 17 
sections overlaying the cornea (regions A – Q in Figure 2.1).  The presence or 
absence of breakup was graded for each applicable region (transect regions were 
deemed “not applicable” if they enclosed non-corneal anatomy alone).  For 
example, in Figure 2.1, regions M, J, and I show areas of breakup.  The BUA (% 
area exposed) in Figure 2.1 would be calculated as the areas of regions M, J, and 
I, divided by the total of areas A through Q.  If a portion of the region had 
breakup, the whole area was deemed to have breakup and was included in the 
calculation of BUA.  The total number of regions ranged from 15 to 17 depending 
on the position of the lids (e.g. if the upper lid covered the top two regions, only 
15 areas were included).   
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Figure 2.1. Corneal transect grid used to score corneal regions 
 
 
Figure 2.2 shows an example schematic diagram of the percent of corneal 
exposure vs time during a single IBI used to calculate BUA.  In this example, the 
IBI is assumed to follow a partial blink, potentially leaving tear film defects, with 
the consequence that the initial percent of area exposed is non-zero as depicted by 
the diagonal cross hatch area in Figure 2.2.  At some point during the IBI, the tear 
film breakup area begins to increase, and this defines the TFBUT. The rate of 
increase between TFBUT and end of the IBI is represented by the triangular area 
at the right of Figure 2.2.  The manual analysis of the video data provided 
measurements of the percent cornea exposed at time 0 (immediately following a 
blink), at the point of increasing break up area (TFBUT), and of the maximum 
level of tear film breakup at the end of the IBI.  Sequences of these three 
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measurements form sequences of schematic diagrams such as that shown in 
Figure 2.2. From each diagram, BUA was calculated and these were averaged to 
give mean values for the 1 minute observation period.  The units of BUA are (% 
cornea exposed)(sec).  The IBI minus the TFBUT represents the “time-exposed 
interval” (TEI), which can be expressed as a fraction of the IBI.  The steepness of 
the increase in BUA after the TFBUT allows analysis of tear film breakup rates.    
 
Figure 2.2.  Schematic diagram of % corneal area exposed vs time during a 
single IBI  
 
Study Design  
This single-center, single visit, proof-of-concept pilot study was conducted 
according to a protocol approved by an external Independent Review Board.  
Written informed consent was obtained prior to study procedures.  Patient-
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reported and investigator-observed adverse events were captured and monitored 
for the duration of the study.   
This study evaluated both eyes of 10 normal and 17 dry eye subjects.  
Enrolled subjects were at least 18 years of age, demonstrated a corrected visual 
acuity of +0.6 logMAR or better in each eye (Early Treatment of Diabetic 
Retinopathy Study), and were able and willing to avoid ophthalmic medications 
for 2 hours prior to each study visit.  Subjects were excluded from the study if 
they wore contact lenses; had any ocular inflammation, ocular infections, active 
ocular inflammation or preauricular lymphadenopathy; had any significant illness 
that could be expected to interfere with the trial parameters; had any known 
allergy or sensitivity to the test article or its components; had a condition that may 
have put the subject at significant risk, may have confounded the study results or 
may interfered significantly with the subjects participation in the study; or had 
taken any systemic medications known to cause ocular drying on an unstable dose 
within 14 days prior to the visit. Smokers were not excluded from the study.  Dry 
eye subjects were selected based on reported use of artificial tears (no minimum 
use required) and were able and willing to avoid ophthalmic medications for 2 
hours prior to the visit. 
Dry eye subjects were measured by both the new (VCMA) and traditional 
(FS) methods, while normal subjects were measured by the new (VCMA) method 
only. Subjects underwent medical and medication history collection, subject-
graded ocular symptom grading, visual acuity, and slit-lamp biomicroscopy.  
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After a five-minute resting period, conjunctival redness based on the Ora scale (0 
[none] to 4 [severe]), and corneal sensitivity were measured.  After a second five-
minute resting period, primary-gaze blink rate was measured (traditional method 
IBI).  After a third five-minute resting period, evaluations for the new (VCMA) 
method comprised tear film breakup time (TFBUT), interblink interval (IBI), and 
breakup area (BUA) based on the 1 minute video capture.  Evaluations for the 
traditional (FS) method comprised the previously obtained primary-gaze blink 
rate and forced-stare TFBUT.   
Following these evaluations, dry eye subjects were treated bilaterally with 
Refresh Liquigel.  One to two drops per eye (OD, OS) were instilled by a 
technician and confirmed by a second technician. Subjects then repeated the 
aforementioned evaluations 10 (± 1) minutes after artificial tear instillation. For 
the purpose of this paper, the treatment effect was assessed by the VCMA method 
only.   
In summary, the three paradigms relevant to this paper were as follows. 
First, traditional and new methods were used to measure the same set of 34 dry 
eyes prior to treatment. Second, the new method was used to measure 20 normal 
eyes and 34 dry eyes prior to treatment. Third, the new method was used to 
measure for the same set of 34 dry eyes before, and 10 minutes after, treatment 
with artificial tears.     
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Statistical Analysis 
For each eye, derived variables were obtained as averages over the 1 minute video 
period.  These outcomes were used to compare groups using a gamma 
multiplicative model estimated by generalized estimating equation methods (See 
Appendix C).  These models provided estimates for group means, ratios of means, 
95% confidence intervals, and P-values for a test of the equality of means. All 
models were fit using the genmod procedure of SAS version 9.2.("SAS Institute 
Inc. 2009. SAS OnlineDoc® 9.2. Cary, NC: SAS Institute Inc,")  
The comparison between dry eye (34 eyes) and normals (20 eyes) was 
based on 54 eyes in two independent groups.  The age-adjusted version of this 
model was based on a two-factor ANCOVA structure with interaction, with 
groups compared at 47 years, the mean age of the sample.  A comparison of mean 
ages for dry eye and normal subjects was based on a t-test. 
Comparisons between traditional (FS) and new (VCMA) methodologies 
(prior to treatment), as well as between pre-treatment and post-treatment means, 
were based on the same sample of 34 dry eyes. The correlation between groups 
was accommodated for via a sandwich variance estimator based on a working 
independence correlation structure.  
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Results 
The mean ages for the normal (N=10) and dry eye (N=17) subjects were 60.8 and 
24.0 years, respectively.  Five normal subjects and 14 dry eye subjects were 
female.   
 
Comparison of Traditional (FS) and New (VCMA) Methods 
Interblink Interval:  Table 2.2 shows the IBI data from the traditional (FS) and 
the new (VCMA) methods the 17 dry eye subjects.  The mean IBIs for the 
traditional (FS) and new (VCMA) methods were 4.04 and 5.51 seconds, 
respectively, for a ratio of 1.36 (P = 0.043).  
 
Table 2.2.  Comparison of new (VCMA) and traditional (FS) methods in dry eye 
subjects 
Variable New
a
  
(N = 34) 
Traditional 
(N = 34) 
Difference 
(95% CI) 
Ratio  
(95% CI) P-value
b 
Time       
IBI (sec) 5.51 4.04 1.47 1.36  (1.01, 1.84) 0.043 
TFBUT (sec) 3.98 5.82 -1.84 0.68 (0.54, 0.87) 0.002 
TFBUT-truncated 
(sec)c 3.98 3.37
1 0.61 1.18 (0.84, 1.67) 0.348 
a
 N= number of eyes 
b P-values based on correlated gamma multiplicative model 
cTFBUT > IBI set equal to IBI for the traditional method (forced-stare) 
 
Figure 2.3 shows histograms for both methods and a scatter plot for individual 
data points. 
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Figure 2.3. IBI observations for new (VCMA) and traditional (FS) methods for  
34 dry eye subjects.  Figure 3a shows observed (yellow) and modeled (blue 
lognormal) histogram, while figure 3b shows a scatter plot of the new vs 
traditional observations relative to a 45 degree reference line.  Sample means 
were 5.5 for VCMA and 4.0 for FS. 
 
 
(a)                         (b)   
 
 
 
Tear Film Breakup Time: The mean TFBUTs for the traditional (FS) and the new 
(VCMA) methods were 5.82 and 3.98 seconds, respectively, for a ratio of 0.68 (P 
= 0.002), reflecting the very different methods used to measure these values.  To 
provide a more meaningful comparison, TFBUTs for the traditional (FS) method 
were truncated to the corresponding IBI when no TFBUT was observed.  This 
approach gave similar means with a ratio of 1.18 (P = 0.348).  Figure 2.4 shows 
histograms of both methods and scatter plots for individual data points. Figure 
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2.5 shows the corresponding plots using the truncated TFBUT values for the 
traditional (FS) method. 
 
Figure 2.4. TFBUT observations for new (VCMA) and traditional (FS) methods 
for 34 dry eye subjects.  Figure 4a shows observed (yellow) and modeled (green 
lognormal) histogram, while figure 4b shows a scatter plot of the new vs 
traditional observations relative to a 45 degree reference line.  Sample means 
were 4.0 for VCMA and 5.8 for FS. 
(a)                                                         (b) 
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Figure 2.5. Truncated TFBUT observations for new (VCMA) and traditional (FS) 
methods for 34 dry eye subjects.  Figure 5a shows observed (yellow) and modeled 
(brown lognormal) histogram, while figure 5b shows a scatter plot of the new vs 
traditional observations relative to a 45 degree reference line.  Sample means 
were 4.0 for VCMA and 3.4 for FS. 
     (a)                                                                         (b) 
 
 
Comparison of Dry Eye and Normal Subjects 
Table 2.3 summarizes group comparisons for dry eye and normal subjects for all 
observed variables (IBI, TFBUT, BUA) and derived variables (BUA/IBI, Rate).  
Mean IBIs for the dry eye and normal groups were 5.51 and 6.82, respectively, for 
a ratio of 0.81 (P = 0.315).  Mean TFBUTs were 3.98 and 5.39, respectively, for a 
ratio of 0.74 (P = 0.200).  Mean BUAs were 10.61 and 3.42, respectively, for a 
ratio of 3.10 (P = 0.004). 
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Table 2.3.  Comparison of dry eye and normal subjects 
Variable 
Dry Eye 
Subjects 
(N = 34)a 
Normal 
Subjects 
(N = 20) 
Difference 
(95% CI) 
Ratio  
(95% CI) P-value
e 
Time       
IBI (sec) 5.51 6.82 -1.31 0.81  (0.53, 1.22) 0.315 
TFBUTb (sec) 3.98 5.39 -1.41 0.74 (0.46, 1.17) 0.200 
Area       
BUA 10.61 3.42 7.19 3.10 (1.45, 6.65) 0.004 
BUA/IBIc 3.70 0.45 3.25 8.22 (3.77, 17.91) < 0.001 
Other       
Rated 7.67 2.37 5.30 3.24 (1.57, 6.66) 0.001 
aN= number of eyes 
b
 Video-capture-derived TFBUT: TFBUT > IBI set equal to IBI  
c BUA/IBI (%) = BUA (% of cornea exposed x sec) divided by IBI (sec) 
d
 Rate (%/sec) = rate of increase in BUA (% cornea exposed) / sec 
e P-values based on gamma multiplicative model (Sample output can be seen in 
APPENDIX D) 
 
Groups were compared with respect to two new derived outcomes: BUA/IBI, and 
rate of increase in BUA.  BUA/IBI (in units of % corneal surface/sec) represents 
the fraction of corneal surface at risk or exposed.  For the dry eye and normal 
groups, BUA/IBI means were 3.70 and 0.45, respectively, for a ratio of 8.22 (P < 
0.001).  Figure 2.6 shows the relationship between BUA and IBI. Values for 
normal subjects clustered in the center of the IBI axis, while dry eye subjects were 
distributed across a wider range of IBI values and displayed elevated BUA values. 
For the dry eye and normal groups, the mean rate of increase in BUA was 7.67 
and 2.37, respectively, for a ratio of 3.24 (P = 0.001).   
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Figure 2.6.  Scatter plot of Breakup Area(BUA) vs. Inter-blink Interval (IBI). The 
parameter BUA/IBI represents the fraction of the corneal surface that is at risk 
(exposed); the units are % corneal surface/sec. The BUA/IBI data are represented 
for normal subjects (circles) and dry eye subjects (crosses). 
 
 
 
The above comparisons were based on unadjusted comparisons and thus may be 
influenced by other differences between the two groups.  Indeed, groups did differ 
with respect to mean age (normal = 24 and dry eye = 60.8, P< 0.001), and for this 
reason the data were fit using an age adjusted model.  The age adjusted results 
were qualitatively similar (Table 2.4). 
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Table 2.4.  Comparison of dry eye and normal subjects adjusted for age 
Variable Dry Eye (N = 34)a 
Normal 
(N = 20) 
Difference 
(95% CI) 
Ratio  
(95% CI) P-value
e 
Time       
IBI (sec) 7.14 3.26 3.88 2.19  (0.39, 12.17) 0.371 
TFBUTb (sec) 5.57       3.87 1.70 1.44 (0.22, 9.27) 0.701 
Area       
BUA 4.07 0.05 4.02 74.6 (4.3, 1303) 0.003 
BUA/IBIc 1.07 0.02 1.05 59.6 (3.1, 1132) 0.007 
Other       
Rated 3.85 0.01 3.84 364.6 (20.5, 6488) < 0.001 
aN= number of eyes 
bbVideo-capture-derived TFBUT: TFBUT > IBI set equal to IBI  
cBUA/IBI (%) = BUA (% of cornea exposed x sec) divided by IBI (sec) 
d
 Rate (%/sec) = rate of increase in BUA (% cornea exposed) / sec 
e P-values based on age-adjusted gamma multiplicative model 
 
 
Detection of Treatment Effect 
Table 2.5 summarizes group comparisons for dry eye subjects pre- and post-
treatment with artificial tears for all observed variables (IBI, TFBUT, BUA) and 
derived variables (BUA/IBI, Rate).   Mean IBIs post- and pre-treatment were 7.70 
and 5.5, respectively, for a ratio of 1.40 (P = 1.118).  Corresponding means for 
TFBUT were 6.50 and 3.98 (ratio = 0.74, P = 0.034), and for BUAs were 6.75 and 
10.61 (ratio = 0.64, P = 0.091). In the case of the derived variables, for the post- 
and pre-treatment groups, BUA/IBI means were 2.16 and 3.70 (ratio = 0.59, P = 
0.001), and for BUAs were 6.75 and 10.61 (ratio = 0.64, P = 0.091).  
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Corresponding mean rates of increase in BUA were 15.39 and 15.30 (ratio = 1.01, 
P = 0.985). 
 
Table 2.5.  Comparison of treatment effect in dry eye subjects 
Variable Post Instillation (N = 34)a 
Pre Instillation 
(N = 34) 
Difference 
(95% CI) 
Ratio  
(95% CI) P-value
e 
Time       
IBI (sec) 7.70 5.51 2.19 1.40  (0.92, 2.12) 0.118 
TFBUTb (sec) 6.50 3.98 2.53 0.74 (1.04, 2.57) 0.034 
Area       
BUA 6.75 10.61 -3.87 0.64 (0.38, 1.07) 0.091 
BUA/IBIc 2.16 3.70 -1.53 0.59 (0.42, 0.81) 0.001 
Other       
Rated 15.39 15.30 0.09 1.01 (0.56, 1.82) 0.985 
aN= number of eyes 
abVideo-capture-derived TFBUT: TFBUT > IBI set equal to IBI  
cBUA/IBI (%) = BUA (% of cornea exposed x sec) divided by IBI (sec) 
d
 Rate (%/sec) = rate of increase in BUA (% cornea exposed) / sec 
e P-values based on correlated gamma multiplicative model  
 
Figure 2.7 shows BUA vs IBI for the dry eye subjects pre- and post-instillation of 
artificial tears. Even though the mean values for BUA and IBI were different, 
there is no obvious separation of the groups.  
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Figure 2.7. BUA (% corneal surface) versus IBI (seconds) for 34 dry eyes before 
(blue crosses) and after (green stars) instillation of artificial tears. 
 
 
Discussion 
This paper introduces a new method for evaluating ocular surface protection 
under normal visual conditions and, as such, is more clinically relevant than the 
traditional Forced-Stare method.  A key feature of the new VCMA method is that 
it allows for the simultaneous capture of TFBUT, IBI, and BUA while the subject 
is blinking normally.   While forced-stare TFBUT certainly identifies 
abnormalities in the tear film of dry eye subjects relative to normal subjects (as 
evidenced by over 30 years of reports(M. B. Abelson, et al., 2002; Holly, 1973; 
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Lemp, 1973; Lemp, et al., 1975; Smith, et al., 2008)), the new VCMA method 
affords this comparison in the natural setting.  
One objective of this study was to compare the traditional (FS) and the 
new (VCMA) methods.  To best understand the advantages of the VCMA 
method, it is of interest to compare the methods in terms of the traditional (FS) 
variables: IBI and TFBUT.   In the VCMA method, IBI and TFBUT were 
recorded under natural conditions.  In contrast, in the traditional (FS) method, 
TFBUT is recorded under forced-stare conditions and IBI under natural blink 
conditions. Despite the fact that IBI was recorded under natural conditions for 
both methods, the significant difference observed in this study between the IBI 
values generated by the two methods could reflect the fact that the blink counter 
equipment used in the FS method only counted complete blinks, whereas the 
VCMA method counted all blinks.  The two methodologies are fundamentally 
different in the measurement of TFBUT.  In the VCMA method, TFBUT is 
captured in a natural state while in the FS method, it is not.  As a consequence, 
comparisons of TFBUT between the two methods require that the TFBUT from 
the traditional (FS) method be truncated at a value equal to the IBI (because in the 
new VCMA method, TFBUT cannot exceed the IBI).  Analysis using the 
truncated data allows for both methods to be compared in a meaningful way.    
A second objective of this study was to compare dry eye and normal 
subjects.   In this study, as expected, dry eye subjects had lower IBIs and TFBUTs 
than normal subjects, although neither difference was statistically significantly.  
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However, BUA, BUA/IBI, and the rate of increase of BUA were significantly 
different between the dry eye and normal subjects, indicating the diagnostic utility 
of these new variables.  It appears that  some dry eye subjects compensate for tear 
film instability and ocular surface discomfort by blinking more rapidly, thus 
avoiding elevated levels of BUA.  The value of the derived variables in the 
VCMA method, in particular BUA/IBI, is the ability to identify both 
compensating and non-compensating subjects.  We note that differences in BUA 
and rate between dry eye subjects and normal subjects have been reported 
elsewhere, but these authors collected the TFBUT and BUA data under forced-
stare conditions. (Begley, et al., 2006; Liu, et al., 2006)  While we acknowledge 
that the age difference between the groups may be a potential limitation of this 
study, an age adjusted analysis of the data provided qualitatively similar results. 
The final objective of this study was to compare the effect of treatment 
with artificial tears in dry eye subjects.  The area variables (BUA, BUA/IBI) were 
both able to detect a treatment effect.  The analysis made possible by the VCMA 
methodology indicated that the treatment with artificial tears increased TFBUT 
but had no effect on rate of increase in BUA.   
        One potential limitation of this study involves the corneal transect grid.  The 
corneal grid was chosen as more precise interpretation of the NEI scale for 
inclusion of more detail and to add specificity, although according to the grid 
method, any breakup in a region is deemed breakup in the entire region.  This 
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may reduce precision and overestimate breakup, however the use of ratios of 
breakup means in the analysis should minimize any bias.   
In summary, there is clinically relevant value in an analysis based on tear 
film stability measured in the context of a natural blink pattern.   While the 
traditionally used variables of IBI and TFBUT are useful, the data presented in 
this paper suggest that BUA is an important additional variable.  Furthermore, 
BUA/IBI illustrates the potential of combining BUA with traditional variables.  
The manual data analysis used in this study was time consuming but provided the 
proof of principle.  Studies are underway to automate the data collection and 
analysis process.  
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CHAPTER 3 
 
VALIDATION AND VERIFICATION OF THE OPI 2.0 SYSTEM 
 
 
 
Background 
Reduced tear film stability is a key driving factor in the development of dry eye. 
The measurement of tear film breakup time (TFBUT) using fluorescein with 
forced-stare is a well established clinical metric for evaluating the health of the 
pre-corneal tear film.(M. B. Abelson, et al., 2002; Holly, 1973; Lemp, 1973; G. 
W. Ousler, 3rd, Hagberg, et al., 2008) More recently, the development of the 
ocular protection index (OPI) was an important step in evaluating the interaction 
between blinking and TFBUT.  This tool has been used in numerous 
observational studies and clinical trials and has been widely adopted by 
clinicians.(Crampton, et al., 2007b; D'Arienzo, et al., 2007; G. W. Ousler, 3rd, 
Hagberg, et al., 2008; G. W. Ousler, Emory, Welch, & Abelson, 2002a; G. W. 
Ousler, et al., 2007; Rolando, Autori, Badino, & Barabino, 2009; Simmons & 
Vehige, 2007; Torkildsen, Ousler, & Gomes, 2008; Wilcox Hagberg, Ousler III, 
Casavant, Welch, & Abelson, 2005a)   However, our increased understanding of 
the complexities of blink physiology and tear film breakup suggests that this 
methodology has the potential to be improved upon.  First, TFBUT and interblink 
interval (IBI) measurements are performed at different times. Second, TFBUT is 
evaluated using the forced-stare technique, which is not representative of the 
physiological action of an unaltered blink pattern.  Third, this methodology 
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provides no information on what occurs on the ocular surface between actual tear 
film breakup and the next blink, which is the point of corneal affliction. 
In order to address these shortcomings, the OPI 2.0 System was developed 
to evaluate ocular surface protection under normal visual conditions.  The 
approach yields a real-time measurement of percent cornea exposed (tear film 
breakup area or BA) for each IBI during a one minute video.  The system also 
provides a simultaneous measurement of TFBUT and IBI.  Utilizing this method, 
the mean breakup area (MBA) and the OPI 2.0, mean breakup area/interblink 
interval (MBA/IBI), are calculated and analyzed.  Initially, a method of 
retrospective manual analysis of fluorescein staining video data was utilized with 
the OPI 2.0 System.(R. Abelson, et al., 2011) In this method, which we refer to as 
video capture with manual analysis (VCMA), a panel of examiners evaluated the 
integrity of the tear film and determined IBI and TFBUT by manually stopping 
the video to note and confirm the time stamp, and record the time of each blink 
and the first appearance of a micelle within each IBI.  This method of BA 
evaluation utilized a sectoral transect of the corneal surface. Grading was made 
based on a binary evaluation of breakup within each region. A given region was 
counted as fully broken if any breakup was observed in that area regardless of the 
actual extent of exposure.  Results utilizing the VCMA method demonstrated 
successful differentiation between normal and dry eye subjects; however, this 
methodology required numerous technician hours to manually grade the area of 
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corneal coverage and did not reach the desired level of precision.(R. Abelson, et 
al., 2011)  
To improve the efficiency of the analysis, a complex set of algorithms 
were developed in order to automate the analysis of video footage collected.  The 
processing of a video consists of two stages. The first is an image segmentation 
stage during which the corneal image is extracted from the background of the 
video frame using a template matching algorithm.   The second stage consists of 
measurement of exposed area from the image sequence.  The areas of exposure 
are summed pixel by pixel and divided by the mean corneal area over the entire 
video. This is to account for small variations in palpebral fissure width, and the 
calculation yields the average percent area of corneal exposure as a function of 
time. 
The development of the software analysis had three goals: to calculate 
more precise values for the percent of corneal area exposed by way of 
computerized image analysis; to decrease human error (i.e. error introduced by 
the use of a stopwatch in the technician’s calculation as there is an inherent delay 
between the time the doctor can detect a break and the time the stopwatch is 
stopped); and to increase the speed of analysis.  Previous work on tear film 
breakup area has been conducted but it is uncertain how much validation has been 
completed on the procedures used.(Begley, et al., 2006; Harrison, et al., 2008; 
Jansen, Begley, Himebaugh, & Port, 2010) Advances in technology have 
prompted the use of video images to determine BA.   While some techniques 
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measure BA from the last video frame before the IBI, the OPI 2.0 System is 
designed to measure MBA, which is an average of the percent of the cornea 
exposed over the entire video (Figure 3.1).   The goal of adding software analysis 
to the OPI 2.0 System was to accurately measure the amount of MBA on the 
cornea and provide an efficient, clinically relevant measurement of the 
pathophysiology of the ocular surface.   
 
Figure 3.1. Demonstrates data for one patient over 60 seconds of video.  MBA is 
calculated as an average amount of corneal surface exposure over the entire video. 
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Methods: 
Verification 
To calibrate the software analysis and demonstrate that it can correctly identify 
the area of exposure, a set of artificially constructed images were created to mimic 
the visual properties of images captured during an actual clinical session using 
fluorescein staining videography.  The relevant parameters included density, 
breakup dispersion, and image brightness.  Breakup density represented the extent 
of tear film breakup as a percentage of the corneal surface area. Breakup 
dispersion represented the degree to which the exposed areas are distributed over 
the corneal surface, ie the number of individual isolated regions of exposed 
cornea. Image brightness represented the pixel intensity level of the green channel 
of the image. 
In addition to the eight images created to bracket the range of values of the 
three parameters (designated  HHL for high dispersion, high density and low 
brightness, etc), a middle image was created at the mean parameter values to 
create a total of nine images.  To measure the effectiveness of the software, an 
image was output with the areas of detected simulated tear film breakup shown in 
red.  For the purposes of this verification procedure, the artificially constructed 
images created to mimic the visual properties of images captured during an actual 
clinical session using fluorescein staining videography will be referred to as the 
“artificial” images.  The software analysis output of the image with the areas of 
detected simulated tear film breakup will be referred to as the “detected” images.  
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There can be two types of incorrect detections of breakup area with regard to any 
discrepancies seen between the number of pixels detected in real images and the 
detected images: false negatives and false positives.  A false negative detection is 
seen when breakup in the real image is not observed by the software analysis in 
the detected image.  A false positive is seen when the software analysis detects 
breakup in the detected image that is not considered breakup in the real image. 
 
Validation 
The second stage involved using actual video images collected during the 
clinical validation process.   The image properties were selected to correspond to 
the range of image values similar to the artificial images. After the selection, the 
images were graded manually by an expert grader and areas of exposed cornea 
were marked using image editing software in blue.  These images were used as 
ground truths to measure the effectiveness of the software. The software was used 
to output the original image indicating the areas of detected break in red. This 
allowed for a simple visual comparison between red (software detected) and blue 
(technician graded). The images were also compared with regard to pixel count. 
 
Clinical Validation 
A single-center, one visit study enrolling 29 dry eye and 16 normal 
subjects was conducted.  All subjects were enrolled based on qualifying eyes, 
meaning a subject could contribute 1 or 2 eyes. Qualifying eyes included 49 eyes 
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from the 29 dry eye subjects and 29 eyes from the 16 normal subjects, for a total 
of 78 qualifying eyes.  Qualifying eyes for the dry eye subjects were based on 
three inclusion criteria: a forced-stare TFBUT of ≤ 5 seconds  in at least one eye; 
a corneal fluorescein staining score ≥2 (0-4 point Ora scale) in at least one region 
of the eye; and a reported history of dry eye disease or ocular symptomatology 
with the desire to use artificial tears.   Normal subjects were excluded if they had 
a history of dry eye, irritation, or any other ocular problems, wore contact lenses 
or had LASIK eye surgery, or habitually used artificial tears or tear substitutes.  
To ensure that normal subjects were largely free of keratitis, qualifying eyes for 
the normal subjects must also have had a ≤ 1.5 staining score in each region of 
both eyes (0-4 point Ora scale).  A staining score of ≥ 2 in any region of any eye 
was exclusionary.   In addition to forced-stare tear film breakup time, fluorescein 
staining evaluations, all enrolled subjects were measured by the OPI 2.0 System.  
Additionally, all dry eye subjects and a random sampling of four normal subjects 
underwent Schirmer’s test evaluations. 
Three additional analyses were performed looking at worst eye only, 
meaning that each subject only contributed a single eye to each analysis.  The eye 
was defined as “worst” using three separate criteria in three independent analyses; 
first by looking at total staining score, second by looking at forced-stare TFBUT, 
and finally by looking at MBA.   Finally, dry eye and normal groups were 
compared with respect to variability. Ratios of standard deviation were used for 
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Schirmer’s and staining, while ratios of coefficients of variation were used for 
forced-stare TFBUT, IBI, MBA, and OPI 2.0. 
Forced-stare tear film breakup time was evaluated by instilling sodium 
fluorescein solution (5µl, 2% preservative-free) into the inferior conjunctival cul-
de-sac of each eye, and the subject was asked to blink several times to mix the 
fluorescein with their tear film.  The subject was then asked to blink twice and 
then stare without blinking for as long as possible.  The examiner monitored the 
integrity of the tear film through a slit-lamp biomicroscope with an 8 mm 
scanning beam (using an excitation blue filter and a barrier Wratten #12 yellow 
filter), and measured the time from eye opening to the first appearance of micelles 
with a stopwatch.  The eyes were evaluated sequentially (OD, OS).  Two 
measurements were taken and averaged unless the two measurements were both 
less than  10 seconds and differed by more than 2 seconds, in which case a third 
measurement was taken and the two closest of the three were averaged. 
Following the traditional clinical assessments, OPI 2.0 System 
measurements were taken. The examiner instilled sodium fluorescein solution 
(5µl, 2% preservative-free) into the inferior conjunctival cul-de-sac of each eye 
and the subject was asked to blink several times to mix the fluorescein with the 
tear film.   While the subject performed a standard visual task (watching a 
documentary on television from a five foot viewing distance), the eye was 
recorded using a digital video camera (EYECAP IM 900 camera System) at 8x 
magnification at a rate of 15 frames per second (FPS) through a slit-lamp 
  
51
biomicroscope using an excitation blue filter and a barrier Wratten #12 yellow 
filter.  A minimum of one minute of continuous data was recorded for each eye 
with approximately thirty seconds between recordings of the two eyes.   The eyes 
were recorded from right (OD) to left (OS).  Subsequently, a computer program 
analyzed the cornea on a frame-by-frame basis and provided BA for each IBI 
during the one minute video.  From this analysis, MBA and OPI 2.0 were 
calculated and analyzed.  The software also provides a measurement of TFBUT; 
however for the purposes of this paper, this data was not analyzed. 
 
Statistical Analysis 
The comparison between independent dry eye and normal qualifying eyes 
was based on 78 eyes (dry eye = 49, normals = 29). Normal linear models 
estimated by generalized estimating equation (GEE) methods were used for 
staining scores, and Schirmer’s scores. Gamma multiplicative models, also 
estimated by GEE methods, were used for MBA, IBI, OPI 2.0 and forced-stare 
TFBUT. 
These models provided estimates for group means, differences of means 
for linear models, and ratios of means for multiplicative linear models. 
Corresponding 95% confidence intervals, and P-values for tests of equality, were 
calculated. All models were fit using the genmod procedure of SAS version 
9.2.("SAS Institute Inc. 2009. SAS OnlineDoc® 9.2. Cary, NC: SAS Institute 
Inc,")  
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Results 
 
Verification 
The software analysis was able to correctly identify the area of exposure in 
a set of artificially constructed images created to mimic the visual properties of 
actual clinical images captured using fluorescein staining videography.  The OPI 
2.0 System false positive and false negative errors were dependent on the given 
parameters (density, p=0.004; dispersion, p=0.038; brightness, p<0.001) of the 
real images (Figure 3.2).  
 
 
Figure 3.2. The OPI 2.0 System false positive and false negative errors and 
verification of the software analysis (images of LLL (2a), HLH (2b), HHH (2c) 
shown) with designated artificial eye on the left and OPI 2.0 System output with 
the areas of detected simulated tear film breakup in red on the right. 
 
Density 
(p=0.004)1 
Dispersion 
(p=0.038)1
 
Brightness 
(p<0.001)1 
False 
Negative 
False 
Positive 
Total 
False 
Total 
Pixels 
%  Error 
Rate 
L L L 0 18 18 404811 0.0044 
L L H 0 4 4 404670 0.0010 
L H L 0 10 10 404670 0.0025 
L H H 1 6 7 404670 0.0017 
M M M 0 6 6 404817 0.0015 
H L L 5 9 14 404806 0.0035 
H L H 0 0 0 404806 0.0000 
H H L 1 2 3 404670 0.0007 
H H H 0 0 0 404670 0.000 
1The OPI 2.0 System false positive and false negative errors were dependent on 
the given parameters. 
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B. 
 
 
C. 
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For all nine images, out of 3,642,590 pixels, there were a total of 62 false errors, 
yielding a 99.9983% accuracy rate.  Seven of the errors were false negatives 
while 55 were false positives. In the artificial eye designated LLL (low density, 
low dispersion, low brightness, Figure 3.2a), the OPI 2.0 System detected the 
greatest number of false positive and false negative pixels with a total of 18, zero 
of which were false negative and all 18 of which were false positive. In the 
artificial eyes designated HLH (high density, low dispersion, high brightness, 
Figure 3.2b) and HHH (high density, high dispersion, high brightness, Figure 
3.2c), the OPI 2.0 System detected the least number of false positive and false 
negative pixels, both with a total of zero. 
 
Validation 
The software analysis was able to correctly identify the area of exposure in a set 
of video images collected (Figure 3.3).   
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Figure 3.3. The OPI 2.0 System false positive and false negative errors and 
verification of the software analysis using actual videos collected (image of HHL 
(3a) shown) with the technician graded image in blue on the left and OPI 2.0 
System output with the areas of detected simulated tear film breakup in red on the 
right. 
 
Density Dispersion
 
Brightness False 
Negative 
False 
Positive 
Total 
False 
Total 
Pixels 
%  
Error 
Rate 
L L L 8 0 8 325620 0.0025 
L L H 0 0 0 396360 0.0000 
L H L 1852 983 2835 364704 0.7773 
L H H 1169 769 1938 256432 0.7558 
M M M 1654 1021 2675 444730 0.6015 
H L L 740 6168 6908 313040 2.2067 
H L H 1561 4044 5605 282400 1.9848 
H H L 5550 7307 12857 444136 2.8948 
H H H 1516 4386 5902 337640 1.7480 
 
A. 
 
 
 
For all nine images, out of 3,165,062 pixels, there were a total of 38,728 false 
errors, yielding a 98.7764 % accuracy rate.  Fourteen thousand and fifty (14, 050) 
of the errors were false negatives while 24,678 were false positives.  In the 
technician graded eye designated HHL (high density, high dispersion, low 
brightness, Figure 3.3a), the OPI 2.0 System detected the greatest number of false 
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positive and false negative pixels with a total of 12,857, of these, 5,550 were false 
negatives and 7,307 were false positives. While this error rate was the highest at 
2.8948%, it can likely be attributed to a discrepancy in the inaccuracy of the 
technician graded image.  In the technician graded eye designated LLH (low 
density, low dispersion, high brightness) the OPI 2.0 System detected the least 
number of false positive and false negative pixels with a total of zero. 
 
Clinical Validation 
The mean ages for the dry eye (n=29) and normal (n=16) subjects with qualifying 
eyes were 59.08 and 34.03 years, respectively.  A total of 49 and 29 eyes qualified 
for the dry eye and normal subjects, respectively.  Three additional analyses were 
performed looking at the worst eye of both dry eye and normal subjects using 
three separate criteria: worst eye based on staining, worst eye based on forced-
stare TFBUT, and worst eye based on MBA.  Each subject only contributed a 
single eye to each analysis, for a total of 45 eyes per analysis (dry eye = 29, 
normal = 16). For the variability analysis, ratios of standard deviation were used 
for staining, while ratios of coefficients of variation were used for forced-stare 
TFBUT, IBI, MBA, and OPI 2.0. 
 
All Qualifying Eyes 
The Schirmer’s score means for the dry eye qualifying eyes and for the four 
qualifying eyes of the randomly selected normal subjects were 11.938 and 21.000 
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mm, respectively, for a ratio of 0.568 (p=0.330). The forced-stare TFBUT means 
for the dry eye and normal qualifying eyes were 2.599 and 10.908 seconds, 
respectively, for a ratio of 0.238 (p<0.001). Figure 3.4 shows histograms for both 
dry eye and normal qualifying eyes.  
 
Figure 3.4. Average forced-stare TFBUT for dry eye and normal qualifying eyes. 
Observed (yellow) and modeled (green, lognormal) histogram. 
 
 
 
 
The staining score means of the entire cornea for the dry eye and normal 
qualifying eyes were 1.983 and 0.241, respectively, for a ratio of 8.215 (p<0.001). 
The staining score means of the superior region of the cornea for the dry eye and 
normal qualifying eyes were 1.878 and 0.207, respectively, for a ratio of 9.075 
(p<0.001).  The staining score means of the central region of the cornea for the 
  
58
dry eye and normal qualifying eyes were 1.765 and 0.103, respectively, for a ratio 
of 17.065 (p<0.001).  The staining score means of the inferior region of the 
cornea for the dry eye and normal qualifying eyes were 2.306 and 0.414 
respectively, for a ratio of 5.573 (p<0.001). 
The IBI means for the dry eye and normal qualifying eyes were 10.710 
and 7.114 seconds, respectively, for a ratio of 1.506 (p=0.098). The MBA (mean 
percent of the cornea exposed) of the entire cornea for the dry eye and normal 
qualifying eyes was 0.232 and 0.040, respectively, for a ratio of 5.882 (p<0.001).  
The MBA of the central region of the cornea for the dry eye and normal 
qualifying eyes was 0.052 and 0.014, respectively, for a ratio of 3.877 (p=0.029).  
The MBA of the inferior region of the cornea for the dry eye and normal 
qualifying eyes was 0.137 and 0.013, respectively, for a ratio of 10.730 (p<0.001). 
The MBA of the superior region of the cornea for the dry eye and normal 
qualifying eyes was 0.043 and 0.013, respectively, for a ratio of 3.256 (p=0.023). 
Figure 3.5 shows histograms for both dry eye and normal qualifying eyes.  The 
OPI 2.0 (in units of mean % cornea exposed/second) represents the fraction of 
corneal surface at risk or exposed. The OPI 2.0 of the entire cornea for the dry eye 
and normal qualifying eyes was 0.039 and 0.006, respectively, for a ratio of 6.111 
(p<0.001).  The OPI 2.0 of the central cornea for the dry eye and normal 
qualifying eyes was 0.009 and 0.002, respectively, for a ratio of 3.947 (p=0.061). 
The OPI 2.0 of the inferior cornea for the dry eye and normal qualifying eyes was 
0.025 and 0.002, respectively, for a ratio of 15.537 (p<0.001).  The OPI 2.0 of the 
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superior cornea for the dry eye and normal qualifying eyes was 0.005 and 0.002, 
respectively, for a ratio of 1.946 (p=0.120).  Figure 3.6 shows histograms for 
both dry eye and normal qualifying eyes. Figure 3.7 shows mean MBA versus 
IBI for both dry eye and normal qualifying eyes. 
 
Figure 3.5. MBA for dry eye and normal qualifying eyes. Observed (yellow) and 
modeled (brown, lognormal) histogram. 
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Figure 3.6. OPI 2.0 for dry eye and normal qualifying eyes. Observed (yellow) 
and modeled (black, lognormal) histogram.  
 
 
 
 
 
Figure 3.7. MBA (mean % of the cornea exposed) versus IBI for dry eye (blue) 
and normal (red) qualifying eyes.  Figure 7A is shown on a linear scale, while 
figure 7B is shown on a logarithmic scale. 
 
A.                                                                   B.      
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Worst Qualifying Eye 
Results for worst qualifying eye based on staining, forced-stare TFBUT, and 
MBA are numerically similar to the analysis for all qualifying eyes. The staining 
scores means for the entire, central, inferior, and superior cornea were statistically 
significant for dry eye and normal worst eyes based on staining, forced-stare 
TFBUT, and MBA (Table 3.1).  The forced-stare TFBUT means were 
statistically significant for dry eye and normal worst eyes based on staining, 
forced-stare TFBUT, and MBA (Table 3.1). 
 
Table 3.1. Mean staining scores for the entire, central, inferior, and superior 
cornea for dry eye and normal worst eyes based on staining, forced-stare TFBUT, 
and MBA 
 
 
The MBA of the entire and inferior cornea was statistically significant for dry eye 
and normal worst eyes based on staining, forced-stare TFBUT, and MBA (Table 
3.2).  The OPI 2.0 of the entire and inferior cornea was also statistically 
significant for dry eye and normal worst eyes based on staining, forced-stare 
TFBUT, and MBA (Table 3.2). 
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Table 3.2.  MBA and OPI 2.0 calculations for the entire, central, inferior, and 
superior cornea for dry eye and normal worst eyes based on staining, forced-
stare TFBUT, and MBA 
 
 
 
Variability Analysis 
Generally, dry eye qualifying eyes showed greater variability than normal 
qualifying eyes; typically dry eyes were twice as variable (Table 3.3).   
 
Table 3.3.  Dry eye and normal groups compared with respect to variability.  
Ratios of standard deviation were used for Shirmer’s and staining, while ratios of 
coefficients of variation were used for forced-stare TFBUT, IBI, MBA, and OPI 
2.0. 
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This is also demonstrated graphically in Figure 3.7.  The dry eye qualifying eyes 
had higher variability for MBA and IBI while the normal qualifying eyes were 
clustered along the x-axis.  The coefficients of variations for MBA for the entire 
cornea of dry eye and normal qualifying eyes were 8.72 and 4.29, respectively, 
for a ratio of 2.03 (p=0.282).  The coefficients of variations for the OPI 2.0 of the 
entire cornea for dry eye and normal qualifying eyes were 4.08 and 1.59, 
respectively, for a ratio of 2.57 (p=0.022). 
 
 
Discussion 
 
Our enhanced understanding of the complexities involved with tear film breakup 
and blink physiology led to an alternative method for the evaluation of ocular 
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surface protection under normal visual conditions.  Although forced-stare TFBUT 
has been a standard diagnostic tool for over 40 years, it does not provide sensitive 
information about the overall health of the tear film, namely what occurs after the 
break in the tear film. As such, the OPI 2.0 System implements fully automated 
software algorithms which provide a real-time measurement of corneal exposure 
(breakup area, BA) for each interblink interval (IBI) during a one minute video.  
From this system, MBA and OPI 2.0 are calculated and analyzed to garner a more 
complete picture of ocular surface health.  The retrospective manual analysis 
originally used, however, required numerous technician hours to manually grade 
the area of corneal coverage.  The development of the software analysis allows for 
a frame-by-frame analysis of percent of corneal area exposed and utilizes 
computer programs to increase the speed of analysis.  The computer program 
minimizes human error or bias and achieves the outcomes in a more precise 
manner. 
The OPI 2.0 System was able to distinguish between a group of pre-
defined dry eye and normal subjects by way of both MBA and OPI 2.0 in 
statistically significant fashions.  Utilizing the software analysis allows for much 
more precise calculations of MBA and OPI 2.0 than the manual analysis.  This 
can be attributed to the fact that grading for the manual analysis was made based 
on a binary evaluation of breakup within each region, where a given region was 
considered to have breakup in that area regardless of the actual extent of 
exposure.  In contrast, the software analysis provides an actual pixel count of BA, 
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which in turn affords a more precise assessment.  Additionally, the manual 
analysis provides average measurements of the percentage of cornea exposed for 
the 1-minute observation period at only time 0 (immediately following the blink), 
at the time of tear film breakup, and at the maximum level of tear film breakup at 
the end of the IBI.  The software analysis, however, analyzes the cornea on a 
frame-by-frame basis, accounting for individualized points of breakup area. 
The OPI 2.0 System also allows for a transect analysis to calculate 
regional variation over the cornea by analyzing corneal exposure on the basis of 
inferior, central and superior regions as well as for the entire cornea.  One 
advantage for the use of a transect is the measurement of tear film dispersion (as 
defined by the verification section).  While the use of a transect is not required 
because the OPI 2.0 System detects breakup area points individually, the use of a 
transect allows for the assessment of tear film breakup patterns by region.   The 
evaluation on a region-by-region basis parallels other clinical assessments such as 
staining grading.  On an aggregate basis, the results of this study suggest that 
there may be a relationship between MBA and staining, as an increase in MBA of 
the dry eye population was consistent with higher staining scores. The results of 
this study also indicate that certain regions of breakup, in particular the inferior 
region, may be important indicators of dry eye.  The worst eye analysis confirmed 
our interest in the inferior region of the cornea as a key indicator of dry eye, 
although further research is warranted. 
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While the goals of this study were to verify and validate the software 
analysis, the OPI 2.0 System may also be used to classify dry eye patients into 
subgroups.  Dry eye patients are largely variable, due in part to varying disease 
states, diurnal variations, extensive visual tasks or environmental stressors that 
may exacerbate or influence dry eye signs and symptoms.(Davis, et al., 2006; 
Karson, et al., 1981; Miljanovic, Dana, Sullivan, & Schaumberg, 2007; Patel, 
Henderson, Bradley, Galloway, & Hunter, 1991; Walker, Lane, Ousler, & 
Abelson, 2010)   In this study, dry eye patients were typically twice as variable as 
normal patients, which may be indicative of various subgroups of dry eye patients 
based on minimal or significant ocular surface exposure and IBI. These various 
subgroups may represent underlying variations in disease pathophysiology in 
addition to a distinct opportunity for advances in potential therapies. 
It is evident that forced-stare TFBUT alone does not provide enough information 
to adequately categorize and assess dry eye patients.  The OPI 2.0 System allows 
us to calculate and analyze MBA and OPI 2.0.   MBA is a global way of assessing 
the percent of cornea exposed, while OPI 2.0 provides information on tear film 
stability by factoring the IBI to garner a more complete understanding of overall 
ocular surface health.    Possible limitations of this study include the small normal 
population analyzed, the measurement of Schirmer’s on only four randomly 
selected normal subjects, and the conduct of the study without a therapeutic agent.  
Studies are underway employing the OPI 2.0 System to assess the therapeutic 
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value of a study drug in a clinical trial setting.  Further research to understand the 
relationship between MBA, OPI 2.0 and potential dry eye subgroups is necessary. 
 
 
 
 
 
 
 
 
CHAPTER 4 
A SINGLE-CENTER STUDY EVALUATING THE EFFECT OF THE 
CONTROLLED ADVERSE ENVIORNMENT (CAE) ON TEAR FILM 
STABILITY 
 
 
Background 
Dry eye disease is a term used to describe a collection of disorders with a shared 
diagnosis of tear film dysfunction, leading to decreased visual acuity, ocular pain, 
burning, and the potential for corneal scarring.("The epidemiology of dry eye 
disease: report of the Epidemiology Subcommittee of the International Dry Eye 
WorkShop (2007)," 2007)  Prevalence is highest in older individuals and in 
women, as well those who have previously undergone laser vision correction. The 
most recent reports suggest that moderate to severe dry eye currently affects 
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between five and ten million Americans, with estimates of ten times that number 
world-wide.(Pflugfelder, 2008) Current treatments include artificial tears, tear 
plugs, or immune-suppressant drugs such as cyclosporine, but these treatments are 
often ineffective for many dry eye sufferers, and so the unmet need for new 
therapeutics is significant.  
  Knowledge of the pathophysiology of dry eye has made considerable 
progress in recent years, and what was once thought to be a condition due simply 
to insufficient tear production is now recognized as a multi-factorial collection of 
diseases.  This is a result of significant strides in basic research in ocular surface 
biology, in combination with improvements in clinical assessment techniques 
such as corneal staining, blink pattern analysis, and various measures of tear film 
stability. In two recent papers we described the stepwise development of our 
improved method of tear film analysis which we have designated as OPI 2.0 
System.(Kellerman, et al., 2004; Ousler GW, et al., 1999)  This method combines 
a number of optimized parameters with automated data capture and analysis to 
generate a more objective, quantitative measure of tear film dynamics.  These 
features have the potential to substantially enhance tear film metrics, and 
represent a key advance over previous methods of tear film analysis.   
  Tear film stability and blink behavior are inexorably linked; the tear film 
is established by the sweeping, squeegee-like action of the lids, and rate and 
pattern of blinks is, in turn, modulated by feedback input from corneal sensory 
nerves.("The epidemiology of dry eye disease: report of the Epidemiology 
  
69
Subcommittee of the International Dry Eye WorkShop (2007)," 2007) Efforts to 
measure properties of the tear film led to the development of tear film break-up 
time (TFBUT), a methodology in which subjects are asked to refrain from 
blinking while an observer monitors the integrity of the tear film.("The 
epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the 
International Dry Eye WorkShop (2007)," 2007)  This “forced stare” approach 
allowed the first estimates of inherent tear film stability and provided the means 
to address how different disorders, drug treatments, or environmental conditions 
might impact the physiochemical properties (and therefore, functional attributes) 
of the tear film.("The epidemiology of dry eye disease: report of the 
Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)," 
2007; G. W. Ousler, et al., 2005)  Standards developed with this method were > 
10 seconds for normals, and < 10 seconds for subjects with dry eye.("The 
epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the 
International Dry Eye WorkShop (2007)," 2007; G. W. Ousler, et al., 2005) 
Subsequent studies have indentified limitations to both the methodologies used to 
measure TFBUT, as well as the metric itself.  For example, reducing and 
standardizing the quantity of fluorescein used led to a modification of reference 
values of TFBUT to a mean value of 7 seconds for normal subjects, and 2.5 
seconds for those with dry eye.(M. B. Abelson, et al., 2002)  Most recently we 
have developed a measure of tear film stability under conditions of natural, rather 
than forced stare blinking.(Ousler GW, et al., 1999)  By capturing the natural 
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dynamics of the tear film with automated methods it was possible to extend our 
studies of the interaction between blinking and TFBUT.(Crampton, et al., 2007b; 
D'Arienzo, et al., 2007; Kellerman, et al., 2004; G. W. Ousler, 3rd, Hagberg, et 
al., 2008; Ousler GW, Emory TB, Welch D, & MB., 2002; G. W. Ousler, et al., 
2007; Simmons & Vehige, 2007)    
 Blinking is a reflex function regulated by a combination of autonomic 
inputs and sensory feedback due to environmental conditions. Blink rate is known 
to increase under adverse conditions(Ousler GW, et al., 2002) such as those 
presented by the Controlled Adverse Environment (CAE), an established clinical 
model that provides a standardized approach to studying investigational 
treatments of dry eye.(G. W. Ousler, et al., 2005)  This model affords a 
controlled, reproducible environment that challenges the eyes of all patients 
equally and for the same amount of time, and exacerbates the signs and symptoms 
of dry eye by regulating humidity, temperature, airflow, lighting conditions, and 
visual tasking.("The epidemiology of dry eye disease: report of the Epidemiology 
Subcommittee of the International Dry Eye WorkShop (2007)," 2007; Rolando, et 
al., 2009) Assessment of both blink behavior and tear film stability led to 
development of the Ocular Protection Index (OPI), a tool used in observational 
and clinical studies designed to evaluate the interaction between blinking and 
TFBUT in studies of dry eye.(Crampton, et al., 2007b; D'Arienzo, et al., 2007; G. 
W. Ousler, 3rd, Hagberg, et al., 2008; Ousler GW, et al., 2002; G. W. Ousler, et 
al., 2007; Simmons & Vehige, 2007; Torkildsen, et al., 2008) Originally, OPI was 
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a ratio of inter-blink interval (IBI) and TFBUT; lower values, and particularly 
values less than one were associated with increased risk of keratitis, since, on 
average, break-up of the tear film and subsequent corneal exposure would occur 
prior to the next blink.(G. W. Ousler, 3rd, Hagberg, et al., 2008)  In a recent study 
we described an improvement upon this method that employs automation of both 
break-up and blink data capture, and use of a revised estimate of corneal surface 
exposure based upon the mean break-up area (MBA) rather than time;(Ousler 
GW, et al., 1999) we refer to this new metric as OPI 2.0. 
The OPI 2.0 System is designed to evaluate ocular surface protection 
under a normal blink pattern and normal visual conditions, and implements fully 
automated software algorithms which provide a real-time measurement of corneal 
exposure.  The system provides a simultaneous measurement of TFBUT, breakup 
area (BUA), and IBI. From this, the MBA and OPI 2.0 (MBA/inter-blink interval) 
are calculated and analyzed. In an earlier paper we established that this automated 
data analysis method provides values comparable to those obtained by manual 
analysis of  video-captured data with a significantly higher degree of 
precision.(Ousler GW, et al., 1999)  The OPI 2.0 System demonstrated a robust 
ability to distinguish between dry eye and normal subjects, and the software 
analysis allowed for precise calculations of ocular surface exposure and ocular 
surface protection metrics.  
  In this study, we explore the ability of the OPI 2.0 System to identify the 
changes and modifications of the tear film after exposing dry eye subjects to the 
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Controlled Adverse Environment (CAE).  A key aspect of the CAE is its utility to 
distinguish sub-populations of dry eye patients. Subjects challenged by 
environmental changes (such as those presented by the CAE) normally respond 
with some degree of physiological compensation, and previous studies have 
shown that the ability of these mechanisms to adequately compensate for 
environmental challenges is reduced in those with dry eye.(G. W. Ousler, 3rd, et 
al., 2002)  The nature and extent of the compensatory response will likely be a 
reflection of the underlying tear film pathology. These compensatory 
mechanisms, such as changes in blink rate or reflex tearing, are likely to impact 
properties such as those measured using the OPI 2.0 System. A primary goal in 
developing new or refined metrics is their use as tools to identify and characterize 
patient sub-populations, especially in multi-factorial diseases such as dry eye. As 
the next step in the validation of OPI 2.0 System-based measures, we examined 
dry eye subjects before, immediately after, and 30 minutes after a 90-minute CAE 
challenge.  
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Methods 
Inclusion criteria   Subjects were recruited from an existing database of dry eye 
patients; a total of 33 subjects were enrolled.  Criteria for inclusion in the database 
included a history of dry eye, use of artificial tears, and a Schirmer's test score of 
< 5 mm in at least 1 eye.  Enrolled subjects were at least 18 years of age, had a 
history of use or desire to use an eye drop for dry eye symptoms within the past 6 
months, and had a best corrected visual acuity (BCVA) of +0.7 or better assessed 
by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes.  
Subjects also had to satisfy each of the following criteria at baseline: a forced-
stare TFBUT of < 5 seconds in at least 1 eye; a deficient OPI (< 1) during at least 
30% of inter-blink intervals as determined by a trained technician; and a total 
corneal fluorescein staining score of ≥ 3, based on the sum of the central, 
superior, and inferior regions of the cornea as anatomically defined by the Ora 
scale.   
 
Exclusion criteria   Subjects were excluded from the study if they had clinically 
significant anterior blepharitis in the opinion of the investigator, were diagnosed 
with on-going ocular infection (bacterial, viral, or fungal) or active ocular 
inflammation (e.g., follicular conjunctivitis); wore contact lenses in the previous 
week;  had used any eye drop in the 4 hours prior to the study; had previously had 
laser in situ keratomileusis (LASIK) surgery or any other ocular surgery in the 
past year; were currently taking any topical ophthalmic prescription or over-the-
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counter (OTC) solutions, artificial tears, gels or scrubs that could not be 
discontinued for the duration of the trial; had used Restasis® in the previous 30 
days; had a systemic disease, or uncontrolled medical condition that could 
interfere with study measurements or subject compliance; were currently pregnant 
or nursing; or had received another experimental drug or device within 30 days of 
visit. 
 
Study Design This was a single-center study, conducted in one visit that included 
a ninety-minute session in the CAE.  Written informed consent was obtained prior 
to study procedures. Patient-reported and investigator-observed adverse events 
were captured and monitored for the duration of the study.  Fluorescein staining, 
TFBUT, conjunctival redness, and OPI 2.0 System measurements were conducted 
at baseline (prior to CAE exposure).  Subjects were then exposed to CAE for 90 
minutes.  Baseline dry eye assessments and OPI 2.0 System measurements were 
repeated on all subjects immediately following CAE exposure, and again 30 
minutes after exposure.   
The primary endpoint for this study was MBA prior to CAE exposure 
compared to MBA immediately and 30 minutes post-CAE exposure, for subjects 
with pre-CAE MBA values ≥ 0.2.  Secondary endpoints included fluorescein 
staining, TFBUT, and redness prior to CAE compared to fluorescein staining, 
TFBUT, and redness immediately and 30 minutes post CAE exposure. Additional 
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secondary endpoints included video-based measurements collected at all 3 time 
points, including IBI and TFBUT, and palpebral fissure width. 
Statistical Analysis Thirty-three subjects were enrolled in the study. Sixty-five of 
the 66 eyes provided readable videos, and these 65 eyes comprised the complete 
analysis sample. All 33 subjects in the intent-to-treat population met the 
requirements of the per-protocol criteria. We also analyzed two sets of subgroups 
defined by their baseline MBA measure; these were subjects with MBA ≥ 0.2 
(n=30) defined by the primary efficacy endpoint, and a second group with an 
initial MBA ≥ 0.5 (n=19).  
Demographic variables (age, sex, duration of dry eye disease) were 
summarized by means and standard deviations. Variables derived from the one 
minute videos were MBA – the primary variable – along with OPI2, BR, IBI, and 
palpebral fissure. These variables were obtained pre-CAE, post-CAE, and 30 
minutes post-CAE. Other secondary variables collected at the same time points 
were BUT, corneal fluorescein staining, and conjunctival redness. In addition, 
ocular discomfort was collected every 5 minutes during the 90-minute CAE, and 
these measurements gave rise to additional variables: average discomfort during 
the CAE, and tearing. We define tearing as the time at which discomfort either 
reduced or plateaued at a value less than the maximum, based upon previous 
studies demonstrating that this plateau is associated with a compensatory tearing 
response.(G. W. Ousler, 3rd, et al., 2002).  
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For those variables with long right-tailed distributions (including MBA, 
OPI2, BR, IBI, palpebral fissure, and BUT) we used a gamma multiplicative 
model to obtain estimates for pre-CAE and post-CAE means, ratios of means, 
95% confidence intervals, and P-values for tests of equality. Corneal fluorescein 
staining and conjunctival redness were analyzed using normal linear models. We 
used a generalized estimating equation to accommodate for the within-subject 
correlation between eyes for both models. For the latter purpose, a sandwich 
variance was used in conjunction with a working independence correlation 
structure. All models were fit using the GENMOD procedure of SAS version 
9.2.("SAS Institute Inc. 2009. SAS OnlineDoc® 9.2. Cary, NC: SAS Institute 
Inc,")  
For variables measured pre- and post-CAE, bivariate relationships were 
obtained via correlations between change scores (e.g., post-CAE MBA minus pre-
CAE MBA versus pre-CAE BR minus post-CAE BR). These change scores were 
also correlated with variables collected in the CAE (average discomfort, and 
tearing [score = 1 if there was tearing within 90 minutes, score = 0 otherwise]), 
and demographic variables of age, duration of dry eye disease, and gender. 
 
Results 
In this single visit study, we examined the effect of the CAE on tear film mean 
breakup area (MBA) for subjects with confirmed dry eye disease.  A total of 33 
dry eye subjects completed the study with 65 qualified eyes entered into the 
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analysis algorithm.  One video file was corrupted during the course of collection 
and could not be included in the analysis.  No treatment was administered in the 
course of the study.   
The demographics of the study populations were generally representative 
of the larger population of all dry eye patients.("The epidemiology of dry eye 
disease: report of the Epidemiology Subcommittee of the International Dry Eye 
WorkShop (2007)," 2007) The study population was 34% men, had a mean age of 
64 years and had experienced dry eye disease for an average of 13.4 years; a 
similar demographic profile described all of the sub-populations analyzed in this 
study, as summarized in Table 4.1.  
 
Table 4.1.  Demographics of study populations.  
 
Subjects Age ± SD %  Male 
Years with 
Dry Eye MBAI 
 
    
All eyes (n=65) 64.1 ± 10.8 34 13.4 ± 12.4 0.55 ± 0.85 
 
    
MBA > 0.5 (n=19) 61.9 ± 14.4 21 14.5 ± 14.8 1.51 ± 1.05 
MBA > 0.2 (n=35) 64.5 ± 12.2 40 14.2 ± 14.5 0.96 ± 0.98 
MBA < 0.5 (n=46) 64.9 ± 9.0 39 13.0 ± 11.4 0.15 ± 0.14 
MBA < 0.2 (n=30) 63.6 ± 9.0 27 12.4 ±  9.5 0.06 ± 0.06 
 
The primary endpoint was the change in MBA between the baseline, pre-CAE 
values and MBA values determined immediately and 30 minutes after exposure to 
the CAE for subjects with initial MBA measures of 0.2 or greater. The change in 
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MBA for 3 subject populations, including those with initial MBA
 
scores < 0.2, is 
shown in Figure 4.1A.  
 
Figure 4.1. A Comparison of endpoints before and after CAE.  Graphs include 
data for the primary efficacy endpoint, MBA in subjects with MBAI > 0.2. 
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Subject with higher initial MBA are those with more severe dry eye, and we 
found that in this population, as well as the entire subject population, exposure to 
the CAE caused a significant decrease in MBA. This figure also shows that for 
those subjects with less severe dry eye (initial MBA, MBAI, <0.2), there is a trend 
toward increased MBA which is not statistically significant. Figure 4.1B and 
4.1C show comparisons of two additional metrics in these 3 populations; blink 
rate and corneal staining.  The change in blink rate observed over the course of 
the study is interesting in that while the population as a whole increased 
significantly, the group with initial MBA > 0.2 did not exhibit this increase 
(Figure 4.1B and Table 4.2). Corneal fluorescein staining is noteworthy for 
several reasons.  First, the difference between those with initial MBA > 0.2 and 
those < 0.2 is significant (p < 0.001), confirming our premise that those with 
higher MBA scores have more severe dry eye. Second, all subjects show 
significant increases in staining over the course of the visit, as expected for 
exposure to the adverse environment of the CAE (Figure 4.1C, Table 4.2).  Of 
note, this increase in corneal staining occurs regardless of the change in MBA 
observed for the various subject populations.  
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Table 4.2.  CAE effects on measures of dry eye. Mean values all endpoints, 
for three measured time-points. Top, all eyes (n=65); bottom, eyes with 
initial MBA (MBAI) > 0.2 (n=35).  * = pval < 0.001;   † = pval < 0.01 as 
compared with pre-CAE value.  
 
All eyes (n=65)        
 MBA 
Blink 
rate 
Palprebral 
Fissure 
Corneal 
Staining Redness 
OPI 
2.0 TFBUT IBI 
Pre-CAE 0.55 22.21 1.34 1.68 1.53 0.19 3.77 3.6 
 
Post-CAE 0.26* 29.01* 1.24* 2.34* 2.35* 0.08† 3.82 3.29 
30 min- 
Post-CAE 0.31† 26.15† 1.28* 2.46* 2.22* 0.12 4.09 3.35 
MBAI > 0.2  (n=35) 
 
 MBA 
Blink 
rate 
Palprebral 
Fissure 
Corneal 
Staining Redness 
OPI 
2.0 TFBUT IBI 
Pre-CAE 0.96 20.56 1.35 1.85 1.67 0.33 3.89 4.41 
 
Post-CAE 0.37* 24.12 1.25* 2.37* 2.47* 0.11* 4.05 4.74 
30 min-Post-
CAE 0.41* 23.72 1.28 2.55* 2.41* 0.14* 4.21 4.36 
 
 
Secondary endpoints included blink rate, palpebral fissure size, corneal staining, 
conjunctival redness, OPI 2.0, TFBUT, and IBI.  The mean values for these 
parameters are shown in Table 4.2; differences and p-values between pre-CAE 
and post-CAE values are shown in Table 4.3.   
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Table 4.3.  Difference values for primary and secondary endpoints in different 
subpopulations. Values represent the change from pre- to post-CAE measures.  
Subpopulations are based upon the initial mean break-up area (MBAI) measure. 
Shaded areas highlight statistically significant changes in subpopulations.  
 
 
MBA Blink Rate 
Palprebr
al 
Fissure 
Staining Redness OPI 2.0 TFBUT IBI 
ALL 
N=65 
-0.29 
(p<0.001) 
6.8 
(p<0.001) 
-0.11 
(p<0.001) 
0.52 
(p<0.001) 
0.80 
(p<0.001) 
-0.11 
(p=0.003) 
0.17 
(p=0.661) 
-0.30 
(p=0.935) 
MBAI > 
0.5 
(N=19) 
-1.11 
(p<0.001) 
-1.75 
(p=0.488) 
-0.08 
(p=0.053) 
0.65 
(p<0.001) 
0.71 
(p<0.001) 
-0.41 
(p<0.001) 
0.40 
(p=0.533) 
0.65 
(p=0.315) 
MBAI > 
0.2 
(N=35) 
-0.59 
(p<0.001) 
3.56 
(p=0.088) 
-0.10 
(p<0.001) 
0.52 
(p<0.001) 
0.80 
(p<0.001) 
-0.21 
(p<0.001) 
0.17 
(p=0.661) 
0.03 
(p=0.935) 
MBAI < 
0.5 (N=46) 
0.05 
(p=0.216) 
10.33 
(p<0.001) 
-0.12 
(p<0.001) 
0.67 
(p<0.001) 
0.87 
(p<0.001) 
0.02 
(p=0.191) 
-0. 09 
(p=0.666) 
-0.70 
(p=0.003) 
MBAI < 
0.2 
(N=30) 
0.06 
(p=0.026) 
10.58 
(p<0.001) 
-0.11 
(p<0.001) 
0.83 
(p<0.001) 
0.85 
(p<0.001) 
0.02 
(p=0.024) 
-0. 07 
(p=0.778) 
-0.70 
(p=0.006) 
 
The major finding is the statistically significant decrease in the MBA immediately 
following CAE exposure.  MBA values 30 minutes post-CAE were also 
significantly lower than baseline, although there was some recovery between the 
two post-CAE time points. As expected, both fluorescein staining and redness 
increase with CAE exposure (Tables 4.2 and 4.3).  Blink rate and palpebral 
fissure width also decreased significantly across the population, at both post-CAE 
times. In contrast, mean IBI and TFBUT changed only minimally, and not 
significantly. Table 4.3 summarizes the difference scores for all endpoints, and 
shows the same pattern of significance for primary and secondary endpoints seen 
in mean value comparisons.   
Based upon the pattern of decreased MBA and increased blink rates, we 
examined a second set of subpopulations that were defined using a higher 
threshold of initial MBA (> 0.5; n = 19). These subjects had a higher initial 
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corneal staining score, and exhibited a more pronounced decrease in MBA in 
response to CAE exposure (Table 4.3, Figure 4.2A).  Analysis of these sub-
populations (initial MBA values greater or less than either 0.2 or 0.5) suggested 
that the MBA metric may provide the means to distinguish between individuals 
who respond in the CAE with differing compensatory mechanisms. Comparison 
of subjects with either high or low MBA shows that there is a clear, statistically 
significant difference in the way these two groups respond to the CAE. Figures 
4.1A and 4.2A show that the decrease in MBA observed in full study population 
is due to the decrease in this more severe subpopulation; note that for the 2 lower 
MBAI groups the mean value increases slightly over the course of the CAE 
exposure (Table 4.3).  A second distinction between those with low versus high 
initial MBA values is shown in Figures 4.1B and 4.2B; despite a decrease in 
MBA during the CAE, subjects with high MBA values show no change in blink 
rate, while those with low initial MBA values increase their blink rate in the CAE 
by almost 50% (Table 4.3).  Reduction in palpebral fissure accompanies this 
increase in blink rate. 
Tear film break-up time has been used as a standard metric in dry eye 
studies for many years, but results from this study suggest that it does not reflect 
the changes in dry eye signs and symptoms resulting from CAE exposure. Figure 
4.2C and Tables 4.2 and 4.3 show that none of the populations examined in this 
study show a significant change in TFBUT, despite the fact that all other metrics 
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associated with dry eye, including corneal staining, ocular redness, and 
discomfort (not shown) increase over the time course of the CAE.  
 
Figure 4.2.  Subpopulation Comparisons. Mean values pre, post and 30-min post 
CAE for two alternative sub-populations. MBAI > 0.5 (n=19) and MBAI < 0.5 
(n=46). 
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We next did a correlation analysis to test whether specific endpoints might show 
an association with MBA changes; this data is summarized in Table 4.4 for the 
population as a whole, and for the more severe subjects (MBAI > 0.2).   
 
Table 4.4.  Pearson correlation coefficients between MBA and secondary 
endpoint measures. Significant values (p < 0.05) are shaded.  
 
 
Tearing Blink rate Fissure Staining Redness TFBUT IBI 
 
MBAI > 0.2 
(n=35) 
0.336 
(p=0.048) 
0.399 
(p=0.0174) 
0.203 
(p=0.242) 
- 0.194 
(p=0.234) 
0.263 
(p=0.127) 
-0.162 
(p=0.353) 
- 0.344 
(p=0.043) 
All subjects 
(n=65) 
0.177 
(p=0.159) 
0.338 
(p=0.0059) 
0.141 
(p=0.260) 
0.0169 
(p=0.894) 
0.183 
(p=0.145) 
- 0.151 
(P=0.230) 
- 0.341 
(P=0.005) 
 
 
Of the endpoints analyzed, only tearing and blink rate (and the related parameter, 
IBI) were significantly correlated with MBA measures. In addition, all endpoints 
except IBI showed a positive correlation with MBA in the full study population. 
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When this same analysis was applied to the high and low MBA subpopulations, 
the correlation between blink rate and MBA is restricted to the high MBA 
population, while subjects in the low MBA population exhibit an inverse 
correlation these two parameters. This distinction indicates that the two 
subpopulations may be responding to the CAE with different compensatory 
mechanisms. Taken together, our results suggest that subjects in the low MBA 
group ameliorate the effects of the CAE, at least in part, by increasing their blink 
rate, while the high MBA group does not. Despite this lack of change in 
compensatory metrics, subjects in the high MBA group exhibit a significant 
decrease in MBA and therefore are clearly responding to the CAE in some way. 
Throughout the course of CAE exposure, subjects were asked to rate their ocular 
discomfort (not shown). The values for all groups display a slow, consistent 
increase in scores over the time course of the CAE, and none of differences 
between group scores are statistically significant at any time point.  This suggests 
that discomfort alone cannot explain the differences in responses seen in the two 
groups.  
 
Discussion 
Dry eye disease is an exceeding complex disease because of the variety of 
etiologies and the overlapping, interacting sensory elements and response 
mechanisms in place designed to maintain an optimally tuned tear film.  
Identification of endpoints that are both meaningful and measurable has been 
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problematic. The study presented here represents one step in the process of 
establishing robust quantitative metrics for clinical studies.  In particular, our goal 
has been to identify measures that are responsive in clinical models designed to 
replicate the disease process, and are capable of distinguishing between the 
subpopulations characteristic of this disease. The data presented here establish 
that the OPI 2.0 system and the measure of MBA can provide the assessment 
tools necessary to meet this goal. 
The key finding of this study is that MBA is significantly decreased in dry 
eye subjects following CAE exposure, and this decrease identifies a 
subpopulation of dry eye subjects.  In contrast, the traditional metric of tear film 
stability, TFBUT, is not significantly altered by CAE exposure. Patients also 
exhibit significant increases in corneal staining, ocular redness, and decreases in 
palpebral fissure width that are all characteristic of dry eye disease.  Thus, in a 
clinical model which reliably elicits signs and symptoms of dry eye disease, MBA 
provides a useful new metric that is superior to TFBUT. 
Patients completing the CAE exposure fell into two groups.  The first 
group, which comprised about 70% of all subjects, was distinguished by a 
relatively stable MBA which was maintained in part by an increase in blink rate 
and a decrease in palpebral fissure width. These changes indicated they were able 
to respond to the environmental challenge with these (and perhaps other) 
mechanisms in order to maintain a relatively constant corneal surface exposure, as 
measured by MBA.  The second, smaller group of subjects began the study with 
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levels of corneal staining similar to the low MBA group despite a baseline break-
up area that was 10 fold higher. Subjects in this group responded to the CAE by 
lowering their MBA more that 3-fold during the course of the CAE exposure. 
While we speculate that this response employed some combination of increases in 
tearing, mucin secretion, or meibum expression, our study did not examine these 
specific tear film parameters. The net effect of their response however is 
evidenced by the fact that corneal staining between the two groups was 
comparable. Future studies will benefit from inclusion of techniques that can 
monitor changes in these tear film components in the course of CAE exposure.   
Our study has direct impact on the design of therapeutic development 
strategies going forward. First, we have provided direct evidence that break-up 
area, and not break-up time, is the more valuable parameter in studies of induced 
dry eye disease.  Second, we have established that through the metrics of the OPI 
2.0 system we can distinguish subpopulations of subjects who are likely to require 
different therapeutic strategies for successful amelioration of their dry eye signs 
and symptoms. 
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CHAPTER 5 
 
SUMMARY, RECOMMENDATIONS FOR FUTURE 
RESEARCH AND CONCLUSION 
 
Summary 
In this research two new methods of evaluating Tear Film Stability 
simultaneously with IBI were were developed. The first, a manual method, of 
measuring ocular exposure in the context of a natural blink pattern through 
analysis of the variables tear film break-up time (TFBUT), inter-blink 
interval (IBI) and tear film break-up area (BUA).  The second an automated 
method called The OPI 2.0 System implements fully automated software 
algorithms which provide a real-time measurement of corneal exposure 
(breakup area, BA) for each interblink interval (IBI) during a one minute 
video. Finally the validated OPI 2.0 System is used to evaluate subject Tear 
Film Stability when exposed to the Controlled Adverse Environment (CAE) 
for inducing the signs and symptoms of Dry Eye disease. 
In the second chapter the manual methodology is tested: The new 
methodology (video capture manual analysis, VCMA) which involves 
retrospective analysis of video data of fluorescein-stained eyes, taken through 
a slit lamp while the subject watches television, provides TFBUT, and BUA 
for each IBI during the 1 minute video.  Traditional methodology measures 
TFBUT and IBI separately; TFBUT under forced-stare conditions, as 
measured by an examiner using a stopwatch, and IBI while the subject 
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watches television. The Forced-Stare and VCMA methods were directly 
compared in the same set of dry eye subjects.  The VCMA method was 
evaluated for the ability to discriminate between dry eye subjects and normal 
subjects.  The VCMA method was further evaluated in the dry eye subjects 
for the ability to detect a treatment effect before, and 10 minutes after, 
bilateral instillation of an artificial tear solution  
Results:  Ten normal subjects and 17 dry eye subjects were studied.  In the dry 
eye subjects, the two methods differed with respect to mean TFBUTs (5.82 sec, 
FS, and 3.98 sec, VCMA, P = 0.002).  The FS variables alone (TFBUT, IBI) were 
not able to successfully distinguish between the dry eye and normal subjects, 
whereas the additional VCMA variables, both derived and observed (BUA, 
BUA/IBI, breakup rate), were able to successfully distinguish between the dry eye 
and normal subjects in a statistically significant fashion.  TFBUT (P = 0.034) and 
BUA/IBI (P = 0.001) were able to distinguish the treatment effect of artificial 
tears in dry eye subjects.   
Conclusion:  The VCMA methodology provides a clinically relevant analysis of 
tear film stability measured in the context of a natural blink pattern.   
 
In the third chapter the OPI 2.0 System is evaluated for its ability to distinguish 
between dry eye and normal subjects, and more accurately identify breakup area. 
The OPI 2.0 System is utilized to calculate and analyze, the mean breakup area 
(MBA) and the OPI 2.0, mean breakup area/interblink interval (MBA/IBI). In 
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order to verify and validate the OPI 2.0 System, a series of artificial images and 
still image frames captured during an actual clinical session using fluorescein 
staining videography were analyzed.  Finally, a clinical validation process was 
completed to determine the effectiveness and clinical relevance of the OPI 2.0 
System to differentiate between dry eye and normal subjects.   
Results:   Software analysis verification conducted in a set of artificially 
constructed images and in actual videos both saw minimal error rates.  MBA and 
OPI 2.0 calculations were able to distinguish between the qualifying eyes of the 
dry eye and normal subjects in a statistically significant fashion (p<0.001 and 
p<0.001, respectively). As expected, the dry eye subjects had a higher MBA and 
OPI 2.0 than the normal subjects (0.232, dry eye; 0.040, normal and 0.039, dry 
eye; 0.006, normal, respectively). Results for the worst eyes and all qualifying 
analyses based on staining, forced-stare TFBUT, and MBA were numerically 
similar. 
Conclusion:  The OPI 2.0 System accurately identifies the amount of MBA on the 
cornea and represents an efficient, clinically relevant measurement of the 
pathophysiology of the ocular surface.   
 
In the fourth chapter we use the OPI 2. 0 System to evaluate changes in tear film 
stability with respect to other Dry Eye in the Controlled Adverse Environment 
(CAE) model of dry eye disease. Thirty-three dry eye subjects completed a single-
center, one visit, pilot, CAE study.  The primary endpoint was mean breakup area 
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(MBA) as assessed by the OPI 2.0 system. Secondary endpoints included corneal 
fluorescein staining, tear film break-up time, and OPI 2.0 System measurements.  
Subjects were also asked to rate their ocular discomfort throughout the CAE.  
Baseline dry eye endpoints and OPI 2.0 System metrics were measured at 
baseline, immediately following a 90 minute CAE exposure, and again 30 
minutes after exposure. 
Results:   MBA showed a statistically significant decrease between the post-CAE 
measurements and the baseline measure. The decrease is relatively specific to 
those patients with moderate to severe dry eye, as measured by baseline MBA.  
Secondary endpoints including palpebral fissure size, corneal staining, redness, 
and OPI 2.0 also show significant changes in comparisons of pre- to post-CAE 
measurements.  There were also significant correlations observed between MBA, 
blink rate, and palpebral fissure size.  Comparison of MBA responses allowed us 
to identify sub-populations of subjects that exhibited different compensatory 
mechanisms in response to CAE challenge. Of note, none of the measures of tear 
film break-up time showed statistically significant changes or correlations in pre- 
versus post-CAE measures. 
Conclusion: This pilot study confirms that the tear film metric MBA can detect 
changes in the ocular surface induced by a controlled adverse environment, and 
that these changes are correlated with other, established measures of dry eye 
disease.  The observed decrease in MBA following CAE exposure demonstrates 
that compensatory mechanisms are initiated during the CAE exposure, and that 
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this compensation may provide the means to identify and characterize clinically 
relevant sub-populations of dry eye patients.  
 
 
 
Future Research 
The next step in this research is to better understand the link between ocular tear 
film surface compensation, ocular discomfort and other related signs and 
symptoms. Research needs to be done to create “best methods” for identifying the 
correct subpopulation of Dry Eye Patients to receive targeted therapy. There are a 
number of compensation tools through which patients compensate some of which 
are blink pattern, reflex tearing, narrowing of the palpeveral fissure and alteration 
in the constituents of the tear film. Within the tear film itself the different 
constituents and their availability may alter the tear film dynamics. To better 
understand these dynamics a baseline of subjects that display reproducible 
compensatory behavior must be identified. Therefore, as a follow on study it will 
be useful to re-enroll the same subjects that displayed compensation in the 4th 
chapter and re-expose them to the CAE to test if they have similar response. It is 
not well understood at this time if the subjects that displayed decreased MBA 
post-CAE will display this type of compensation on a reliable basis or just 
transiently. If this group does display a similar response then we can hypothesize 
that subgroup classification through the use of measuring compensation is a 
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meaningful method and would have great impact in terms of understanding 
disease and it’s treatment. In this follow on study special effort needs to be taken 
to ensure the environment under which patients are evaluated emulates that of the 
first study as much as possible.  
 
Conclusion 
This research established that the analysis of Tear Film stability within the natural 
blink pattern is a viable, meaningful and accurate method for evaluating Dry Eye 
severity. This was accomplished both using a manual methodology (VCMA) and 
then subsequently using an automated video processing methodology (The OPI 
2.0 System). Both methodologies were validated as useful, reliable tools for 
evaluating Tear Film stability in the context of a natural blink pattern. The current 
gold standard, TFBUT , was shown to have higher variability and a lack of 
specificity in it’s ability to evaluate Dry eye severity changes in subjects before 
and after the CAE; the OPI 2.0 system was able to detect differences in Tear film 
stability before and after subjects exposure to the CAE. It was demonstrated 
through the use of the OPI 2.0 System that subpopulations of Dry Eye Patients 
exist both in terms of compensation and response. In addition meaningful 
correlations were shown between mean breakup area (MBA), staining and 
discomfort.  
 In conclusion MBA is a meaningful endpoint in evaluating Dry Eye 
Severity and the OPI 2.0 system is an accurate and precise tool to measure MBA. 
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APPENDIX C 
 
SAMPLE SAS CODE 
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Independent Normal/Linear Model 
 
proc genmod data=dataset; 
class group; 
model Staining = group / dist=Normal link=Id; 
lsmeans group / diff; 
run; 
 
 
Independent Gamma Multiplicative Model 
 
proc genmod data=dataset; 
class group; 
model IBI = group / dist=Gamma link=Log; 
lsmeans group / diff; 
run; 
 
 
Correlated Normal/Linear Model 
 
proc genmod data=dataset; 
class subj group; 
model Staining = group / dist=Normal link=Id; 
lsmeans group / diff; 
run; 
 
 
Correlated Gamma Multiplicative Model 
 
proc genmod data=dataset; 
class subj group; 
model IBI = group / dist=Gamma link=Log; 
repeated subject = subj / type=exch;    
lsmeans group / diff; 
run; 
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APPENDIX D 
 
SAMPLE SAS OUTPUT – DRY EYE VS NORMAL 
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Group    logIBI                                                Cum.              
Cum. 
        Midpoint                                         Freq  Freq  Percent  
Percent 
                  | 
DryEye      0.3   |************************************     9     9    16.67    
16.67 
            0.9   |************************************     9    18    16.67    
33.33 
            1.5   |********************                     5    23     9.26    
42.59 
            2.1   |************************                 6    29    11.11    
53.70 
            2.7   |************                             3    32     5.56    
59.26 
            3.3   |********                                 2    34     3.70    
62.96 
                  | 
Normal      0.3   |                                         0    34     0.00    
62.96 
            0.9   |********                                 2    36     3.70    
66.67 
            1.5   |****************************             7    43    12.96    
79.63 
            2.1   |************************************     9    52    16.67    
96.30 
            2.7   |********                                 2    54     3.70   
100.00 
            3.3   |                                         0    54     0.00   
100.00 
                  | 
                  ----+---+---+---+---+---+---+---+---+ 
                      1   2   3   4   5   6   7   8   9 
 
                                Frequency 
 
 
 
Sample: Eyes=54, 
y=IBI, Dist=Gamma, Link=Log, AIC=298 
 
group        Est        SE      Mean 
 
Normal      1.92      0.17      6.82 
DryEye      1.71      0.13      5.51 
 
 
 
Parameter    group        Est        SE      Lo95      Hi95     Ratio     Pval 
 
Intercept                1.71      0.13      4.28      7.10      5.51    <.001 
Group_       Normal      0.21      0.21      0.82      1.87      1.24    0.315 
Group_       DryEye      0.00      0.00      1.00      1.00      1.00     . 
Scale                    1.77      0.31      3.49     12.22      5.86     _ 
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Group    logBUT                                    Cum.              Cum. 
        Midpoint                             Freq  Freq  Percent  Percent 
                  | 
DryEye     -0.8   |********                     4     4     7.41     7.41 
            0.0   |******************           9    13    16.67    24.07 
            0.8   |**********************      11    24    20.37    44.44 
            1.6   |************                 6    30    11.11    55.56 
            2.4   |****                         2    32     3.70    59.26 
            3.2   |****                         2    34     3.70    62.96 
                  | 
Normal     -0.8   |                             0    34     0.00    62.96 
            0.0   |                             0    34     0.00    62.96 
            0.8   |********                     4    38     7.41    70.37 
            1.6   |************************    12    50    22.22    92.59 
            2.4   |********                     4    54     7.41   100.00 
            3.2   |                             0    54     0.00   100.00 
                  | 
                  ----+---+---+---+---+---+ 
                      2   4   6   8   10  12 
 
                          Frequency 
 
 
 
Sample: Eyes=54, 
y=BUT, Dist=Gamma, Link=Log, AIC=271 
 
group        Est        SE      Mean 
 
Normal      1.68      0.19      5.39 
DryEye      1.37      0.15      3.95 
 
 
 
Parameter    group        Est        SE      Lo95      Hi95     Ratio     Pval 
 
Intercept                1.37      0.15      2.97      5.25      3.95    <.001 
Group_       Normal      0.31      0.24      0.85      2.18      1.36    0.193 
Group_       DryEye      0.00      0.00      1.00      1.00      1.00     . 
Scale                    1.39      0.24      2.69      7.11      4.03     _ 
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Group    logBUA                                                Cum.              
Cum. 
        Midpoint                                         Freq  Freq  Percent  
Percent 
                  | 
DryEye    -5.25   |****************************             7     7    12.96    
12.96 
          -3.75   |                                         0     7     0.00    
12.96 
          -2.25   |****                                     1     8     1.85    
14.81 
          -0.75   |********************                     5    13     9.26    
24.07 
           0.75   |************************                 6    19    11.11    
35.19 
           2.25   |************************************     9    28    16.67    
51.85 
           3.75   |************************                 6    34    11.11    
62.96 
                  | 
Normal    -5.25   |                                         0    34     0.00    
62.96 
          -3.75   |                                         0    34     0.00    
62.96 
          -2.25   |****************                         4    38     7.41    
70.37 
          -0.75   |********************                     5    43     9.26    
79.63 
           0.75   |****************************             7    50    12.96    
92.59 
           2.25   |************                             3    53     5.56    
98.15 
           3.75   |****                                     1    54     1.85   
100.00 
                  | 
                  ----+---+---+---+---+---+---+---+---+ 
                      1   2   3   4   5   6   7   8   9 
 
                                Frequency 
 
 
 
Sample: Eyes=54, 
y=BUA, Dist=Gamma, Link=Log, AIC=273 
 
group        Est        SE      Mean 
 
Normal      1.23      0.36      3.41 
DryEye      2.36      0.28     10.56 
 
 
 
Parameter    group        Est        SE      Lo95      Hi95     Ratio     Pval 
 
Intercept                2.36      0.28      6.14     18.15     10.56    <.001 
Group_       Normal     -1.13      0.45      0.13      0.79      0.32    0.013 
Group_       DryEye      0.00      0.00      1.00      1.00      1.00     . 
Scale                    0.39      0.06      1.33      1.69      1.47     _ 
